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A B S T R A C T
Background
Central venous catheters (CVCs) play a vital role in themanagement of acute and chronic illness. Dressings and securement devicesmust
ensure CVCs do not dislodge or fall out, provide a barrier protection from microbial colonisation and infection, and be comfortable
for the patient. There is a large range of dressing and securement products available for clinicians to use.
Objectives
To compare the available dressing and securement devices for CVCs, in terms of catheter-related bloodstream infection (BSI), catheter
colonisation, entry- and exit-site infection, skin colonisation, skin irritation, failed catheter securement, dressing condition andmortality.
Search methods
In June 2015 we searched: The Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials
(CENTRAL); The Database of Abstracts of Reviews of Effects (DARE); NHS Economic Evaluation Database (NHSEED); Ovid
MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE; EBSCO CINAHL; six clinical trial
registries and reference lists of identified trials. There were no restrictions based on language or date of publication or study setting.
Selection criteria
We included randomised controlled trials that evaluated the effects of dressing and securement devices for CVCs. All types of CVCs
were included, i.e. short- and long-term CVCs, tunnelled and non-tunnelled, port-a-caths, haemodialysis catheters, and peripherally-
inserted central catheters (PICCs).
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Data collection and analysis
We used standard Cochrane Collaboration methods including independent review of titles and abstracts for relevance, data extraction,
and risk of bias assessment of the included studies by two review authors. Results are expressed using risk ratio (RR) for categorical data
with 95% confidence intervals (CIs). For outcomes best presented as a rate-per-time-period, rate ratios and standard errors have been
used. We performed multiple treatment meta-analyses to rank the effectiveness of each intervention for each outcome.
Main results
We included 22 studies involving 7436 participants comparing nine different types of securement device or dressing. All included
studies were at unclear or high risk of performance bias due to the different appearances of the dressings and securement devices. The
extent of blinding of outcome assessment was unclear in most studies. The quality of evidence varied between different comparisons
and outcomes. We mainly downgraded the quality of evidence for imprecision, indirectness, risk of bias and inconsistency.
It is unclear whether there is a difference in the rate of catheter-related BSI between securement with gauze and tape and standard
polyurethane (SPU) (RR 0.64, 95% CI 0.26 to 1.63, low quality evidence), or between chlorhexidine gluconate-impregnated (CGI)
dressings and SPU (RR0.65, 95%CI 0.40 to 1.05,moderate quality evidence). There is high quality evidence thatmedication-impregnated
dressings reduce the incidence of catheter-related BSI relative to all other dressing types (RR 0.60, 95% CI 0.39 to 0.93).
There is moderate quality evidence that CGI dressings reduce the frequency of catheter-related BSI per 1000 patient days compared
with SPU dressings (RR 0.51, 95% CI 0.33 to 0.78).
There is moderate quality evidence that catheter tip colonisation is reduced with CGI dressings compared with SPU dressings (RR 0.58,
95% CI 0.47 to 0.73), but the relative effects of gauze and tape and SPU are unclear (RR 0.95, 95% CI 0.51 to 1.77, very low quality
evidence). It is unclear if there is a difference in rates of skin irritation or damage when CGI dressings are compared with SPU dressings
(moderate quality evidence) (RR 11.17, 95% CI 0.84 to 149.48).
A multiple treatment meta-analysis found sutureless securement devices as likely to be the most effective at reducing the incidence of
catheter-related BSI (low quality evidence), with CGI dressings ranked second (low quality evidence).
Authors’ conclusions
Medication-impregnated dressing products reduce the incidence of catheter-related BSI relative to all other dressing types. There is
some evidence that CGI dressings, relative to SPU dressings, reduce catheter-related BSI for the outcomes of frequency of infection per
1000 patient days, risk of catheter tip colonisation and possibly risk of catheter-related BSI. A multiple treatment meta-analysis found
that sutureless securement devices are likely to be the most effective at reducing catheter-related BSI though this is low quality evidence.
Most studies were conducted in intensive care unit (ICU) settings. More, high quality research is needed regarding the relative effects
of dressing and securement products for CVCs. Future research may adjust the estimates of effect for the products included in this
review and is needed to assess the effectiveness of new products.
P L A I N L A N G U A G E S U M M A R Y
Dressings and securement for central venous catheters (CVCs)
Background
A central venous catheter (CVC) is a tube that is inserted into a blood vessel to enable the delivery of liquid nutrition, blood, medicine
or fluids (or a combination of these) to a person who is ill. If a CVC is in place the patient does not need to suffer repeated needle
insertions when treatments are due, as tubes can be attached to the CVC, the required fluid pumped in, and then the tubes detached
when appropriate.
CVCs need to be secured adequately, usually with a dressing of some kind, in order to prevent them from becoming dislodged and to
avoid infection (for example, catheter-related bloodstream infections (BSI)), and need to be comfortable for the patient. Many different
types of products are available to secure CVCs, but it is not known which works best.
Review question
The objective of this research was to compare the available dressings and securement devices for CVCs to identify which works best.
What we found
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The researchers searched medical databases up to September 2014, and identified 22 studies with a total of 7436 participants that were
relevant to the research question. The studies investigated the following comparisons:
- nine studies compared sterile gauze with standard polyurethane dressings;
- six studies compared standard polyurethane dressings with chlorhexidine gluconate-impregnated dressings (chlorhexidine gluconate
is an antibacterial disinfectant);
- one study compared standard polyurethane dressings with silver-impregnated dressings (silver compounds may have antibacterial
properties);
- one study compared standard polyurethane dressings with hydrocolloid dressings;
- one study compared ’modern’ gas permeable standard polyurethane dressings with ’old’ (original) standard polyurethane dressings;
- one study compared highly adhesive transparent standard polyurethane dressings with chlorhexidine gluconate dressings;
- one study compared standard polyurethane dressings with sutureless (stitchless) securement devices;
- one study compared sterile gauze with no dressing; and
- one study compared chlorhexidine gluconate dressings with no dressings.
The included studies sometimes did not clearly report the methods they had used to minimise accidental or statistical error, but overall
the methods were adequate.
Analysis of the study results showed that there is high quality evidence that securing a CVC with a dressing impregnated with a
medication (chlorhexidine gluconate-impregnated or silver) reduces catheter-related blood stream infection compared with a dressing
without medication. The results indicated moderate quality evidence for a reduction in the frequency of catheter-related BSI per 1000
patient days (this is a unit used in research that represents patient use; in this case 1000 patient days is equal to 1000 patients using
CVCs for one day, or 500 patients using CVCs for two days, or 250 patients using CVCs for four days, etc.) when a chlorhexidine
gluconate-impregnated dressing was used rather than a standard polyurethane dressing. When the risk of infection with chlorhexidine
gluconate-impregnated dressings was compared with the risk with standard polyurethane dressings in another way (by calculating the
ratio of the risk of infection with one versus the other without taking account to patient days of use) this difference was less clear. A
less direct measure of infection, that is the extent of bacterial colonisation of the tip of the catheter after removal, showed more bacteria
with the standard polyurethane dressing (moderate quality evidence).
The studies that contributed to this research were mainly carried out in intensive care unit settings, where a large number of CVCs are
used for short durations. Other types of dressings and securement products for CVCs that were investigated by the studies analysed
here did not show any observable effects on catheter-related BSI, catheter tip colonisation or any of the other outcomes assessed, such
as skin irritation, failed catheter securement, condition of the dressing and patient death.
More, high quality research is needed to investigate the relative effects of the wide range of dressing and securement products that are
available for CVCs.
This plain language summary is up-to-date as of 5th June, 2015.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Gauze and tape compared to SPU for CVC dressing and securement
Patient or population: pat ients with CVC
Setting: all sett ings
Intervention: gauze and tape
Comparison: standard polyurethane (SPU)
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with standard
polyurethane (SPU)
Risk with Gauze and
tape
Catheter-related blood
stream infect ion
assessed with: as de-
f ined by criteria spec-
if ied by Maki 2006;
Mermel 2009 and
O’Grady 2002
Study populat ion RR 0.64
(0.26 to 1.63)
506
(8 RCTs) LOW 12
75 per 1000 48 per 1000
(19 to 122)
Moderate
113 per 1000 72 per 1000
(29 to 184)
Catheter t ip colonisa-
t ion
assessed with: posit ive
semi-quant itat ive (>15
cfu/ catheter segment‘‘
or quant itat ive (>10 3
cfu/ catheter segment’’
culture f rom a proximal
or distal catheter seg-
ment (O’Grady 2002)
Study populat ion RR 0.95
(0.51 to 1.77)
342
(5 RCTs) VERY LOW 234
413 per 1000 392 per 1000
(211 to 731)
Moderate
619 per 1000 588 per 1000
(316 to 1000)
4
D
re
ssin
g
s
a
n
d
se
c
u
re
m
e
n
t
d
e
v
ic
e
s
fo
r
c
e
n
tra
l
v
e
n
o
u
s
c
a
th
e
te
rs
(C
V
C
)
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to wide 95% conf idence intervals (0.26 to 1.63)
2 Downgraded due to variability in results between studies
3 Downgraded due to outcome being a surrogate measure of catheter-related bloodstream infect ion
4 Downgraded due to wide 95% conf idence intervals (0.51 to 1.77)
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B A C K G R O U N D
Description of the condition
Central venous catheters (CVCs) play an important role in the
management of patients, providing reliable vascular access and a
site for venous pressure monitoring. They are inserted when a pa-
tient requires venous access over an extended period of time, and
allow the intravenous administration of complex drug treatments,
blood products and nutritional support without the trauma asso-
ciated with repeated needle insertions (Webster 2011). Although
mostly used in intensive-care units and oncology settings, CVCs
are increasingly being used in other wards and outpatient settings.
There are multiple types of CVCs in use throughout clinical prac-
tice. A CVC can be designated by: its intended life span (e.g.
temporary or short-term versus permanent or long-term); the site
of insertion (e.g. subclavian vein, femoral vein, internal jugular
vein or peripherally inserted central catheter (PICC)); the path-
way from skin to vessel (e.g. tunnelled versus non-tunnelled); the
physical length (e.g. long versus short) or some other special char-
acteristic(s) (e.g. impregnation with heparin or number of lumens
(lines); O’Grady 2011). More information regarding the variety
of catheters used in clinical practice is included in Appendix 1.
Owing to the invasive procedure necessary for inserting aCVCand
the resulting break in the skin (integument), complications such as
exit-site infections and bloodstream infections can develop (Han
2010). A serious complication of CVCs is catheter-related blood
stream infections (BSI), also known as ’catheter sepsis’. Catheter-
related BSI rates are influenced by patient-related factors, such as
severity and type of illness (e.g. full-thickness burns versus post-
cardiac surgery), by catheter-related factors (such as the condition
under which the catheter was placed and catheter type), and by
institutional factors (e.g. bed numbers, hospital affiliation with
an academic institution; O’Grady 2011). Many studies have es-
timated the incidence of catheter-related BSI, generally report-
ing a range between 1 and 3.1 per 1000 patient days, primarily
within the adult intensive care unit (ICU) setting (Pronovost 2006;
Schwebel 2012), but rates have been shown to decrease to zero af-
ter the introduction of interventions involving handwashing and
skin antisepsis (Han 2010). The attributable cost of catheter-re-
lated BSI has been estimated within the adult ICU population and
varies between USD 3124 and USD 60,536 per event when con-
sidering hospital staffing and consumables (Raad 2007; Schwebel
2012), and is associated with an attributable mortality of 0% to
11.5% (Timsit 2011).
CVCs are foreign objects, and, as such, require their external com-
ponent to be both protected adequately from microbial contami-
nation from the surrounding environment and secured to the skin.
Dressings and securements must ensure CVCs do not dislodge or
fall out (or both), or move within or out of the great veins. This
can occur via movement or pressure on the external component of
the device, through forced removal, or ‘drag’ from infusion tubing
or ‘catching’ on environmental structures (Naimer 2004). Move-
ment of the CVC to a location outside the target placement can
result in line failure or cardiovascular instability. In critical situa-
tions line failure (e.g. the interruption of inotropic support dur-
ing cardiogenic shock) can have catastrophic consequences for the
patient’s morbidity and mortality.
Description of the intervention
There is a plethora of CVC dressings and securement devices from
which clinicians may select. The earliest securement approach
was simple tape or gauze-tape, with plastic film dressings becom-
ing prominent in the 1980s. First-generation occlusive standard
polyurethane (SPU) dressings were later developed to become
semi-permeable to oxygen, carbon dioxide and water vapour (e.g.
OpSite IV 3000®, Smith and Nephew; Tegaderm Plus®, 3M),
as occlusive dressings trap moisture on the skin and so provide
an ideal environment for quick growth of local microflora (Frasca
2010). Each dressing is transparent, permitting continuous visual
inspection of the catheter site. A recent approach to CVC secure-
ment is the bordered polyurethane (BPU) dressing that retains the
clear central polyurethane component of SPU dressings with an
added external adhesive border of foam or cloth fabric to maximise
catheter security (e.g. Tegaderm Advanced®, 3M).
The majority of catheter-related BSI are caused by micro-or-
ganisms found in the patient’s own commensal skin flora, such
as Staphylococcus epidermidis and Staphylococcus aureus (Timsit
2011); consequently, in recent years we have seen the arrival of
medication-impregnated dressings. The most common of these
are the chlorhexidine gluconate-impregnated (CGI) dressings.
These CGI dressings release chlorhexidine gluconate on the un-
derlying cutaneous surface when placed over the catheter inser-
tion site (Arvaniti 2012). Chlorhexidine gluconate is a cationic
biguanide that provides rapid antisepsis because of its broad spec-
trum of germicidal activity against most catheter-related BSI-caus-
ing pathogens (Garland 2001). Chlorhexidine gluconate impreg-
nates thewhole dressing, or is applied using an impregnated sponge
(e.g. Biopatch®) and covered by a transparent polyurethane dress-
ing. Other medication-impregnated dressings include silver-im-
pregnated and iodine-impregnated dressings (Wille 1993). The
iodine-impregnated dressings release free iodine when exposed to
wound exudate, while the silver-impregnated dressings expose the
entrance site to silver ions; both iodine and silver have antimicro-
bial properties. Some researchers recommend the use of hydrocol-
loid dressings for the dressing of CVCs. This type of dressing is
traditionally used on open wound sites to promote moist healing
as the hydrocolloid matrix absorbs excess moisture away from the
skin surface, and so reduces the likelihood of microbial growth
(Nikoletti 1999).
Securement of the CVC is also facilitated by mechanisms other
than dressings. Traditionally, CVCs were routinely sutured in
place, prior to a dressing being applied (O’Grady 2011). In addi-
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tion to this option, clinicians frequently reinforced the device secu-
rity using non-commercial options including sterile strips or non-
sterile tape. Recently, sutureless securement devices (SSD) have be-
come available commercially. These are used in addition to trans-
parent dressings, and use a large adhesive footplate and an underly-
ing padwith an device-locking clasp (e.g. StatLock®, Bard). These
theoretically reduce movement, kinking and flow impedance, and
maximise catheter stabilisation (Yamamoto 2002).
Each of these CVC dressing and securement types has different
therapeutic goals and is readily available for clinicians and patients
to purchase from numerous suppliers, depending upon the treat-
ment setting (e.g. outpatients). The diversity of dressings and se-
curement devices available to clinicians (including variationwithin
each of the types discussed above) makes evidence-based decision-
making difficult in this area. With the availability of increasingly
sophisticated and expensive CVCdressings and securements, prac-
titioners need to know how effective these dressings are compared
with more traditional dressings.
How the intervention might work
The ideal CVC dressing and securement device should:
• provide a barrier that protects from microbial colonisation
and infection, preventing catheter related BSI;
• provide adequate securement to prevent accidental removal,
partial dislodgement and micro-motion, thus preventing CVC
failure;
• be comfortable and non-irritating for the patient;
• be easy to use; and
• be cost-effective.
Several studies have reported the effects of interventions to reduce
catheter-related BSI rates, including maximal sterile precautions
during insertion, skin antisepsis, securement devices and antimi-
crobial catheter coatings (Han 2010; Levy 2005; Timsit 2011).
The role of the CVC dressing in preventing catheter-related BSI
is to provide a protective barrier that prevents migration of skin
organisms at the insertion site into the cutaneous catheter tract -
and subsequent colonisation of the catheter tip - and preventing
direct contamination of the catheter by contact with hands and
other materials (O’Grady 2011).
Why it is important to do this review
Decreasing the incidence of catheter-related BSI and preventing
CVC failure are important objectives with a significant impact on
patient morbidity and mortality, yet there is no consensus on the
optimal dressing or securement type to use with CVCs, despite
more than two decades of research and debate. An earlier Cochrane
review, ’Gauze and tape and polyurethane dressings for CVC’, fo-
cused on only two product types (Webster 2011), and, therefore,
does not address adequately the variety of products now available
in the clinical environment. A large variety of dressings and types
of securement is currently available for use with CVCs, including
medication-impregnated dressings and sutureless securement de-
vices.
O B J E C T I V E S
To compare the available dressings and securement devices for
CVCs, in terms of catheter-related bloodstream infection (BSI),
catheter colonisation, entry- and exit-site infection, skin colonisa-
tion, skin irritation, failed catheter securement, dressing condition
and mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) that evalu-
ated the effects of CVC dressings and securement devices for their
impact on catheter-related BSI, catheter colonisation, entry- and
exit-site infection, skin colonisation, skin irritation, catheter se-
curity, dressing condition or mortality, irrespective of publication
status or language. We would have included controlled clinical
trials (CCTs) only in the absence of RCTs. CCTs are studies in
which the trial involves testing an intervention and a control, with
concurrent enrolment and follow-up of test and control-treated
groups, but themethod of allocation is not considered to be strictly
random (Lefebvre 2011).We also excluded cross-over and cluster-
randomised trials in order tominimise potential bias in accordance
with Reeves 2011.
Types of participants
Any person of any age requiring a CVC in any healthcare or com-
munity setting. All CVCs were included, i.e. short- and long-term
CVCs, tunnelled and non-tunnelled, port-a-caths, haemodialysis
catheters, and peripherally-inserted central catheters (PICCs). For
studies that included other types of vascular catheter, only data
pertaining to CVCs were included.
Types of interventions
We included trials that compared any CVC dressings or secure-
ment device including, but not limited to, the following.
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Dressings
• Gauze and tape.
• Standard polyurethane (SPU) dressings: semi-permeable
and highly permeable.
• Highly adhesive polyurethane dressings.
• Bordered polyurethane (BPU) dressings.
• Chlorhexidine gluconate-impregnated (CGI) dressings.
• Other medication-impregnated dressings.
• Hydrocolloid dressings.
• No dressing.
Securement device
• Sutureless securement devices (SSD).
• Sutures.
• No securement.
Types of outcome measures
Primary outcomes
• Incidence of catheter-related blood stream infection (BSI):
as defined by one of the following three criteria.
◦ Primary bacteraemia/fungaemia with at least one
positive blood culture from a peripheral vein with no other
identifiable source for the BSI other than the CVC, plus, one of:
a positive semiquantitative (> 15 colony-forming units (cfu)) or
quantitative (> 10³ cfu) device culture, with the same organism
(species and antibiogram) isolated from the device and blood
(Maki 2006; O’Grady 2002).
◦ Two blood cultures (one from an CVC hub and one
from a peripheral vein), that both meet the CVC related-BSI
criteria for quantitative blood cultures (three-fold greater colony
count of growth for the same organism as from the peripheral
blood), or differential time to positivity (DTP; growth of the
same microbe from hub drawn blood at least two hours before
growth from the peripheral blood; Mermel 2009).
◦ Two quantitative blood cultures of samples obtained
through two catheter lumens in which the colony count for the
blood sample drawn through one lumen is at least three-fold
greater than the colony count for the blood sample from the
second lumen (Mermel 2009).
Secondary outcomes
• Frequency of catheter-related BSI per 1000 patient days:
catheter-related BSI as previously defined.
• Incidence of catheter tip colonisation: positive semi-
quantitative (> 15 cfu/catheter segment) or quantitative (> 10³
cfu/catheter segment) culture from a proximal or distal catheter
segment (O’Grady 2002).
• Incidence of entry- and exit-site infection: as described by
the trial investigator.
• Incidence of skin/site colonisation: positive semi-
quantitative (> 15 cfu) or quantitative (> 10³ cfu) culture from
the skin around the catheter site (O’Grady 2002).
• Incidence of skin irritation or damage: as described by the
study investigator using a formal assessment tool (e.g. erythema
and dryness scales; Kampf 2005).
• Incidence of failed catheter securement: frequency of
accidental or forced removal or dislocation resulting in CVC
failure.
• Dressing condition/durability: incidence or mean score
using a formal assessment tool (e.g. Pedrolo 2011).
• Mortality from any cause.
Studies must have reported at least one pre-specified outcome, in
accordance with these definitions, in order to be included in this
systematic review.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify reports
of relevant randomised clinical trials:
• The Cochrane Wounds Group Specialised Register (5 June
2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL; The Cochrane Library 2015, Issue 6);
• The Database of Abstracts of Reviews of Effects (DARE;
The Cochrane Library 2015, Issue 6);
• NHS Economic Evaluation Database (The Cochrane
Library 2015, Issue 6);
• Ovid MEDLINE (1946 to June 04, 2015);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, June 04, 2015);
• Ovid EMBASE (1974 to June 04, 2015);
• EBSCO CINAHL (1982 to June 04, 2015).
We used the following search strategy in CENTRAL:
#1MeSH descriptor: [Catheterization, Central Venous] explode
all trees (779 citations)
#2(venous near/3 (catheter* or line*)):ti,ab,kw (1526 citations)
#3(central near/3 (catheter* or line*)):ti,ab,kw (1408 citations)
#4(hickman next catheter*):ti,ab,kw (33 citations)
#5(broviac next catheter*):ti,ab,kw (9 citations
#6(cook next catheter*):ti,ab,kw (4 citations)
#7MeSH descriptor: [Catheters, Indwelling] explode all trees (959
citations)
#8(“implantable vascular access device” or IAVD or PortACath):
ti,ab,kw (3 citations)
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#9(“peripherally inserted central catheter” or PICC):ti,ab,kw (68
citations)
#10(h*emodialysis next catheter*):ti,ab,kw (111 citations)
#11#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
(2414 citations)
#12MeSH descriptor: [Occlusive Dressings] explode all trees (451
citations)
#13MeSH descriptor: [Bandages, Hydrocolloid] explode all trees
(162 citations)
#14MeSH descriptor: [Silver] explode all trees (177 citations)
#15MeSH descriptor: [Silver Sulfadiazine] explode all trees (145
citations)
#16MeSH descriptor: [Polyurethanes] explode all trees (373 cita-
tions)
#17MeSH descriptor: [Iodine] explode all trees (324 citations)
#18MeSH descriptor: [Chlorhexidine] explode all trees (1375 ci-
tations)
#19((occlusive* or hydrocolloid* or silver* or polyurethane* or
permeable or nonpermeable or non-permeable or transparent or
chlorhexidine or iodine* or gauze or tape) near/3 (dressing* or
sponge*)):ti,ab,kw (1184 citations)
#20#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 (3391
citations)
#21#11 and #20 (203 citations)
We adapted this strategy to search Ovid MEDLINE, Ovid EM-
BASE and EBSCO CINAHL, details of these searches can be
found in Appendix 2. We combined the Ovid MEDLINE search
with the Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision; Lefebvre 2011).We combined
the EMBASE search with the Ovid EMBASE filter developed
by the UK Cochrane Centre (Lefebvre 2011). We combined the
CINAHL searches with the trial filters developed by the Scottish
Intercollegiate Guidelines Network (SIGN 2012). There were no
restrictions on the basis of date, study setting, language or publi-
cation status.
We also searched the following clinical trial registers:
• ClinicalTrials.gov (http://www.clinicaltrials.gov/);
• Current Controlled Trials (http://www.controlled-
trials.com/mrct);
• Hong Kong clinical trials register (http://
www.hkclinicaltrials.com);
• Indian clinical trials registry (http://ctri.nic.in/
Clinicaltrials/login.php);
• UK Clinical Trials Gateway (http://www.controlled-
trials.com/ukctr/);
• the World Health Organization (WHO) International
Clinical Trials Registry Platform (http://apps.who.int/
trialsearch/Default.aspx); and
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/ctr-search/search)
Searching other resources
We handsearched bibliographies of all retrieved and relevant pub-
lications identified by these strategies for further relevant studies.
We contacted experts in the field to ask for information relevant
to this review. We also contacted dressing and securement device
manufacturers for unpublished data in order to counteract publi-
cation bias.
Data collection and analysis
Selection of studies
Independently, two review authors (AU and MM) assessed titles
and abstracts of retrieved studies for relevance. After this initial as-
sessment, we retrieved full versions of all potentially eligible stud-
ies. Independently, the same two review authors checked the full
papers for eligibility. We resolved discrepancies between review
authors through discussion and, where required, consulted a third
independent review author (CR). For transparency we have pub-
lished a summary of the selection of studies, including excluded
studies and reasons for exclusion, using the PRISMA flowchart
(Liberati 2009).
Data extraction and management
We extracted details from eligible studies and summarised them
using a data extraction sheet. Due to the large number of studies
included in this review, teams of two review authors reviewed spe-
cific interventions including: CGI dressing studies, gauze studies,
SSD studies, paediatric and neonatal studies, and the remaining
studies. These teams extracted data independently, which were
cross-checked for accuracy and agreed upon. We resolved any dis-
crepancies though discussion and arbitration by a third review au-
thor, when necessary. For studies that were published in duplicate,
we extracted maximal data from all relevant publications, but we
did not duplicate data in analyses. When there were any data miss-
ing from the papers, we attempted to contact the trial authors to
retrieve them.
We used a data extraction sheet to extract summary data from each
trial. The data extraction sheet contained baseline characteristics
of the study participants: their number; age; gender; disease; treat-
ment; type of CVC; dressing or securement, or both; number of
dressing changes during the dwell time of the CVC; and health-
care setting in which the intervention occurred. We listed each
trial’s criteria for participant inclusion and exclusion, a description
of the intervention(s), the number of people randomised to each
intervention, and primary and secondary outcome measures.
Assessment of risk of bias in included studies
Each eligible study was independently assessed for methodolog-
ical quality and bias using the Cochrane Collaboration ’Risk of
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bias’ assessment tool. This tool addresses six specific domains,
namely, sequence generation, allocation and concealment, blind-
ing of participants/care providers, blinding of outcome assessors,
incomplete outcome data, selective outcome reporting, as well as
other issues that potentially may bias the study (Higgins 2011a).
In accordance withHiggins 2011a, assessment for ’other’ bias con-
cerned baseline balance between treatment groups, early cessation
of the trials and commercial sponsorship. We have completed a
’Risk of bias’ table for each eligible study and outcome using the
categories of ’low’, ’high’ or ’unclear’ risk of bias. The criteria for
judging risk of bias assessments (i.e. categories of low, high or un-
clear) were made in accordance with recommendations in Higgins
2011a. Assessment of risk of bias is discussed within the text and
the judgements are presented as a ’Risk of bias’ summary graph,
which summarises judgements by domain, and a ’Risk of bias’
summary figure, which cross-tabulates judgements by study. To-
gether these tools have been used to assess overall risk of bias, in
combination with the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach (Schunemann
2011). The GRADE approach assesses the quality of evidence per
comparison and outcome throughout five factors: risk of bias, in-
directness of the population, interventions and outcomes, incon-
sistency amongst studies, imprecision (including information size
and confidence intervals) and publication bias.
We undertook data extraction for risk of bias from the in-
cluded studies using the same approach explained above in Data
extraction and management. We extracted and summarised data
using a data extraction sheet. Teams of two review authors re-
viewed specific interventions, extracted data independently and
cross-checked the data for accuracy and agreement. We resolved
any discrepancies through discussion and arbitration by a third
review author, when necessary. We contacted trial authors if data
pertaining to risk of bias was missing, including protocol-based
assessments of selective outcome reporting. The review authors
searched trial registries, as previously described, to identify research
protocols to enable assessment for selective outcome reporting.
Measures of treatment effect
Our primary analysis involves pair-wise comparisons of treatment
effect between dressing and securement types, using all the de-
scribed outcomes. For dichotomous outcomes, we have calculated
the risk ratio (RR) plus 95% confidence intervals (CI). For the
outcome best presented as a rate-per-time-period (i.e. catheter-
related BSI per 1000 patient days), we have used rate ratios (RaR)
and standard errors (SE) to inform inverse-variance analysis. This
analysis required the provision of patient days per intervention
group. As CVCs are inserted for variable durations, the rate of
catheter-related BSI per 1000 patient days was used to describe
the variable frequency of catheter-related BSI across the catheter
duration between the CVC securement and dressing options.We
undertook meta-analysis whenmore than one study used the same
intervention and reported the same outcome.
In addition to the main pair-wise analysis described above, in or-
der to inform clinical decision-making we planned to undertake
pair-wise comparisons using the ’clustering’ of interventions on
the basis of patient treatment goals and outcomes. These cluster-
ing comparisons were done because of the heterogeneity of popu-
lations that use CVCs, and the way their goals for treatment differ.
In order to minimise bias, these clustering comparisons were iden-
tified prior to undertaking the analyses. We planned to compare
the following.
Catheter-related BSI
• Medication-impregnated dressings (CGI, povidone-iodine
and silver-impregnated etc.) versus non-impregnated dressings
(SPU, BPU, gauze and tape, hydrocolloid).
• CGI-impregnated dressings versus all other medication-
impregnated dressings (povidone-iodine, silver etc.).
• Silver-impregnated dressings versus all other medication-
impregnated dressings (povidone-iodine, CGI etc.).
• Povidine-iodine impregnated dressings versus all other
medication-impregnated dressings.
• Gauze and tape versus SPU and BPU.
Incidence of skin irritation or damage
• Hydrocolloid dressing versus all others.
• Gauze and tape versus SPU and BPU.
• CGI-impregnated dressings versus SPU and BPU.
Failed catheter securement
• BPU versus all non-bordered dressings (SPU, hydrocolloid).
• SSD versus all other dressing types.
• No dressing versus all other dressing types.
Unit of analysis issues
The majority of the included RCTs randomised participants and
not their CVCs. Two studies recruited participants multiple times
for multiple CVCs: Carrer 2005 recruited 82 participants with
107 CVCs; Chambers 2005 recruited 95 participants with 114
CVCs. These studies falsely assumed independence of the CVCs,
which provides a potential risk of bias. For the current review, at-
tempts were made to contact the study authors in order to obtain
the results for one CVC per participant, but these data were not
available. For these studies, data involving CVCs as the unit of
analysis were included. Future updates of this review will incor-
porate studies that used CVCs as the unit of analysis, rather than
participants, in a sensitivity analysis to examine for potential risk
of bias.
In accordance with Higgins 2011b, for included studies that in-
volved the comparison of multiple interventions using a single
control, we split the ’shared’ control group to avoid additional unit
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of analysis issues. We did this to distribute the appropriate study
weight and maintain independent comparisons fairly.
Dealing with missing data
When there was evidence of missing data, we attempted to contact
the study authors to request the missing information. When after
several attempts to contact the trial author the missing data were
not provided, we analysed the available data only. We emailed
the authors of ten included studies to ask for further information
and clarification of key aspects of their study methods and results.
Study authors from seven of the ten trials responded (de Barros
2009; Levy 2005; Nikoletti 1999; Olson 2004; Shivnan 1991;
Timsit 2009; Timsit 2012), with four authors able to provide all
information required (de Barros 2009; Levy 2005; Timsit 2009;
Timsit 2012). We have also addressed the potential impact of the
missing data on the findings of the review in the Discussion.
Loss to follow-up and attrition data were adequate and well de-
scribed by ten studies (Arvaniti 2012; Brandt 1996; Chambers
2005; Garland 2001; Giles 2002; Pedrolo 2011; Ruschulte 2009;
Shivnan 1991; Timsit 2009; Timsit 2012). Five studies had high
levels of attrition and loss to follow-up (Carrer 2005; Conly 1989;
le Corre 2003; Levy 2005; Nikoletti 1999). The remaining seven
studies provided inadequate information regarding loss to fol-
low-up and attrition for us to assess for bias (de Barros 2009;
Hagerstrom 1994; Hill 2010; Olson 2004; Roberts 1998; Wille
1993; Yamamoto 2002).
Assessment of heterogeneity
A random-effects model was used for data synthesis because of
predicted clinical heterogeneity. We considered clinical, method-
ological and statistical heterogeneity and undertook an assessment
of comparability of the studies prior to meta-analysis. We investi-
gated the degree of statistical heterogeneity, that is, variation be-
tween the true intervention effects underlying the different stud-
ies, by a combination of methods. This involved visual inspection
of the meta-analytic model and interpretation of the Chi² and I²
statistics that examine the total variance across studies due to het-
erogeneity rather than chance (Higgins 2003).
Assessment of reporting biases
We reported each outcome separately. We used funnel plots to
assess reporting biases for the main analysis (Egger 1997; Analysis
1.1). Any asymmetry of the funnel plot may indicate possible
publication bias.
Data synthesis
Initially we conducted a structured narrative summary of the
studies included in the review to inform the development of
meta-analysis. We entered quantitative data into Review Man-
ager (RevMan) 5.3 and analysed them using the RevMan analysis
software (RevMan 2014). We pooled data for meta-analysis us-
ing RevMan 5.3, and used a random-effects model because of the
clinical heterogeneity.
Multiple treatments meta-analysis (MTM)
Due to the number of treatment options available for CVC secure-
ment and dressing, a ’multiple-treatments meta-analysis’ has been
undertaken in order to assist clinicians in making meaningful-de-
cisions (Higgins 2011b; Salanti 2008). These analyses provide a
’ranking’ of each intervention for example by the probability of
each intervention being the best in terms of a particular outcome.
MTM data synthesis
Calculation of log risk ratios and their standard errors was repeated
in Stata (StataCorp 2011). The log rate ratios and their standard
errors were calculated in Stata (using the ’network setup’ com-
mand; White 2012). Values of zero incidences were replaced with
0.1 for MTM.
MTM quality and inconsistency assessments
Risk of bias assessment within the MTM analyses was undertaken
following the principles of the GRADE approach (Schunemann
2011) across the domains of risk of bias, indirectness, inconsis-
tency and imprecision. Network diagrams were developed to dis-
play the network of interventions using nodes and edges. Nodes
represented the competing treatments; the size of the shapes drawn
over the nodes was proportionate to the number of studies where
that intervention was evaluated. The edges represented the avail-
able direct comparisons between pairs of treatments; the thickness
of the edges is weighted by the total number of devices/patients
randomised in that comparison; colour indicated average level of
study limitation due to bias (green=low, yellow=moderate, red=
high) (Chaimani 2013). Contributions matrices (not presented)
were used to identify the most influential comparisons for the net-
work, and to evaluate the quality of evidence for the ranking of
treatments. Based on the bias level (shown with coloured edges
on the network plot) of the most influential comparisons, a deci-
sion was made to downgrade the overall confidence (in the overall
ranking of interventions) for reasons of study limitations, or not
to downgrade (Salanti 2014).
Indirectness due to differences between study populations, inter-
ventions and outcome measures resulting in a lack of transitiv-
ity was also assessed, resulting in further downgrading of confi-
dence where necessary (Salanti 2014). Inconsistency refers to a dis-
agreement between direct and indirect evidence, and overall con-
fidence in the ranking of interventions was downgraded if there
was evidence of inconsistency and/or the overall (common) het-
erogeneity was moderate / high. Inconsistency was assessed with
’ifplot’ in Stata, and was evident at p<0.05. If the mean RoR is
large (e.g. >2), this indicated possible inconsistency even if p>0.05
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(Chaimani 2013). A common heterogeneity was used for all com-
parisons within each loop. The level of common heterogeneity was
considered low at τ 2<0.045 and high at τ 2>1.14 (Salanti 2014),
except at networks without loops. In this case the I2 statistic was
calculated and assessed for intervention pairs (with direct evidence
and more than one study) as low (<25%), moderate (25-75%) or
high (>75%). Rankings (by probabilities of being the best inter-
vention) were produced using ’network rank’ in Stata after running
the consistency model (’network meta c’ in Stata; White 2012).
Confidence in the overall rankingwas considered initially as ‘high’,
and then later downgraded to ‘moderate’, ‘low’ and ‘very low’ as
required.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses for the primary out-
comes, but were unable to complete them due to insufficient data
within each pair-wise comparison.
• Adult participants versus paediatric participants versus
neonatal participants.
• Participants diagnosed with haematology/oncology
conditions versus other participants.
• CVC type (tunnelled versus non-tunnelled, short-term
versus long-term, dialysis versus non-dialysis, PICC versus
centrally-inserted CVC).
• Participants receiving the intervention in an acute versus a
community setting.
• Participants receiving lipid and parenteral nutrition (PN)
versus patients not receiving lipid and PN.
Sensitivity analysis
We planned to perform a sensitivity analysis of primary outcomes
to explore the effects of excluding those studies at high risk of bias
from the final meta-analysis. We planned only to include studies
that were assessed as having a low risk of bias in all key domains,
namely, adequate generation of the randomisation sequence, ad-
equate allocation concealment, and blinding of outcome assessor,
for the estimates of treatment effect. However we were unable
to perform this analysis for the outcome of catheter-related BSI
due to poor reporting. There were insufficient studies in the other
comparisons to permit a meaningful analysis on the remaining
intervention comparisons.
R E S U L T S
Description of studies
Results of the search
The results of the search and selection of studies are summarised in
the PRISMA study flow diagram Figure 1. The search of electronic
bibliographic databases identified 415 records, 69 of which were
duplicates. Searches of clinical trial registries did not identify addi-
tional studies, but the handsearching of bibliographies identified
three studies for potential inclusion. Of the 349 titles screened,
305 were excluded. We screened 44 full-text articles for potential
inclusion, and excluded 21, listing the reasons for their exclusion
in theCharacteristics of excluded studies tables.We identified four
studies which we have not yet retrieved in full text or are await-
ing information from the trial authors (Broadhurst 2014; Calvino
2014; Gu 2014; Pedrolo 2014).
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Figure 1. Study flow diagram.
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Included studies
The 22 included studies, with a total of 7436 participants, are
described in Characteristics of included studies. The studies were
RCTs conducted in 25 countries, including the USA (five studies),
Canada (three studies), France and Australia (two studies each),
Greece, Italy, New Zealand, Spain, Turkey, Sweden, Israel, Brazil,
Germany and the Netherlands (one study each).
Population and setting
Studies were undertaken in intensive care units (ICUs; Arvaniti
2012; Carrer 2005; Garland 2001; Hill 2010; Levy 2005;
Nikoletti 1999; Pedrolo 2011; Roberts 1998; Timsit 2009; Timsit
2012), oncology and haematology units (Chambers 2005; Olson
2004; Ruschulte 2009; Shivnan 1991), including bone marrow
transplantation units (Brandt 1996), haemodialysis centres (de
Barros 2009; Hagerstrom 1994; le Corre 2003), general surgical
units (Giles 2002; Wille 1993; Yamamoto 2002), and throughout
the hospital (Conly 1989). One study continued to study partic-
ipants after discharge from acute care (le Corre 2003).
Eleven studies restricted participation to adults (Arvaniti 2012;
Brandt 1996; Chambers 2005; le Corre 2003; Nikoletti 1999;
Olson 2004; Pedrolo 2011; Timsit 2009; Timsit 2012; Wille
1993; Yamamoto 2002); one study to paediatric participants (Levy
2005); two studies to neonates (Garland 2001; Hill 2010); while
two studies had a combination of adults and children (Conly 1989;
Shivnan 1991). The age of participants was not described in six
studies (Carrer 2005; de Barros 2009; Giles 2002; Hagerstrom
1994; Roberts 1998; Ruschulte 2009).
The types of CVCs studied were restricted to tunnelled CVCs in
four studies (Brandt 1996; Chambers 2005; Hagerstrom 1994;
le Corre 2003), non-tunnelled, percutaneous CVCs in six studies
(Carrer 2005; Levy 2005; Nikoletti 1999; Pedrolo 2011; Roberts
1998; Ruschulte 2009), peripherally inserted central catheters
(PICCs) in two studies (Hill 2010; Yamamoto 2002), and a com-
bination of CVC types in four studies (Conly 1989;Garland 2001;
Timsit 2009; Timsit 2012). The type of CVC investigated was
not described in six studies (Arvaniti 2012; de Barros 2009; Giles
2002; Olson 2004; Shivnan 1991; Wille 1993).
Interventions and comparisons
As expected, the studies includedmany different interventions and
comparisons. Researchers compared:
• sterile gauze with standard polyurethane (SPU) in nine
studies (Brandt 1996; Carrer 2005; Conly 1989; de Barros 2009;
Giles 2002; Hagerstrom 1994; le Corre 2003; Pedrolo 2011;
Shivnan 1991);
• SPU with chlorhexidine gluconate-impregnated (CGI)
dressings in six studies (Arvaniti 2012; Garland 2001; Levy
2005; Roberts 1998; Ruschulte 2009; Timsit 2009);
• SPU with silver-impregnated dressings in one study (Hill
2010);
• SPU with hydrocolloidal dressing in one study (Nikoletti
1999);
• second generation gaseous permeability SPU with first
generation SPU (old generation SPU) in one study (Wille 1993);
• SPU, highly adhesive transparent dressings with CGI
dressings in one study (Timsit 2012)
• SPU with sutureless securement devices (SSD) in one study
(Yamamoto 2002);
• sterile gauze with no dressing in one study (Olson 2004);
and
• CGI dressings with no dressing in one study (Chambers
2005).
Outcomes
There was variability in the reporting of outcomes. The pri-
mary outcome of catheter-related BSI was reported by 17 stud-
ies (Arvaniti 2012; Brandt 1996; Chambers 2005; Conly 1989;
de Barros 2009; Garland 2001; Giles 2002; Hagerstrom 1994; le
Corre 2003; Olson 2004; Pedrolo 2011; Ruschulte 2009; Shivnan
1991; Timsit 2009; Timsit 2012; Wille 1993; Yamamoto 2002).
Each of these studies defined the outcome of catheter-related BSI
in accordance with the definition of our review. Several other stud-
ies reported catheter infection or sepsis, but did not meet the def-
inition as described in our protocol, these studies are described in
Characteristics of excluded studies.
Eight studies reported the patient day information required for
our secondary outcome of ’frequency of catheter-related BSI per
1000 patient days’ (Arvaniti 2012; Chambers 2005; le Corre
2003; Ruschulte 2009; Timsit 2009; Timsit 2012; Wille 1993;
Yamamoto 2002). We attempted to contact the remaining eight
study authors who had provided catheter-related BSI incidence in
the pair wise comparisons, one provided patient day information
(de Barros 2009), two were unable to locate the data (Olson 2004;
Shivnan 1991), two did not respond (Garland 2001; Pedrolo
2011), and contact information could not be found for the re-
maining three (Brandt 1996; Giles 2002; Hagerstrom 1994).
The remaining secondary outcomes were reported inconsistently.
Twelve studies reported the incidence of catheter tip colonisa-
tion according to our definitions (Arvaniti 2012; Carrer 2005;
Conly 1989; de Barros 2009; Garland 2001; Giles 2002; Levy
2005; Nikoletti 1999; Pedrolo 2011; Roberts 1998; Timsit 2009;
Timsit 2012). Two studies reported the incidence of skin or site
colonisation according to our protocol definitions (Giles 2002;
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Shivnan 1991). The incidence of entry- and exit-site infection was
reported by four studies (Brandt 1996; Chambers 2005; Roberts
1998; Shivnan 1991), skin irritation or damage was reported by
five studies (Garland 2001; Hill 2010; Levy 2005; Pedrolo 2011;
Yamamoto 2002), incidence of failed catheter security by four
studies (Arvaniti 2012; Brandt 1996; de Barros 2009; Yamamoto
2002), and mortality from any cause by four studies (Arvaniti
2012; Chambers 2005; Hill 2010; Pedrolo 2011). The incidence
of dressing durability or condition was assessed using an a priori
definition by one study (Pedrolo 2011), however no studies re-
ported a mean score for dressing condition or durability using a
formal assessment tool.
Due to the small number of studies that reported each outcome,
clustering comparisons were only undertaken for catheter-related
BSI, and medication-impregnated dressings (CGI, povidone-io-
dine and silver-impregnated) versus non-impregnated dressings
(SPU, BPU, gauze and tape, hydrocolloid).
Excluded studies
We excluded 21 studies for the following reasons.
• Study design: the studies were clinical controlled studies,
with sequential assignment rather than randomised allocation
(two studies).
• Population: arterial catheters and CVCs recruited to the
studies, outcomes reported together. We contacted the study
authors, but they were unable to provide separated results (two
studies).
• Confounding interventions: the study involved the
application of specific dosages of skin antiseptics and
administration set changes at different intervals that may have
had a significant impact on the outcome results (one study).
• Outcome definition: outcomes used in the study did not
meet our outcome definitions (16 studies).
• Inadequate data for extraction: the data were not provided
in a way that allowed meaningful extraction, and we were unable
to contact study authors (one study).
A description of each study is available in the Characteristics of
excluded studies table (Crawford 2004;Davidson 1986; Freiberger
1992; George 2011; Keenlyside 1991; Keenlyside 1993; Khattak
2010; Lawson 1986; Little 1998; Lucas 1996; Madeo 1998; Maki
1984; Maki 2000; Neufeld 1991; Olson 2008; Petrosino 1988;
Powell 1982; Powell 1985; Reynolds 1997; Schwebel 2012; Timsit
2010).
Risk of bias in included studies
Figure 2 shows that there is no evidence of funnel plot asymmetry
to indicate potential reporting bias in the included studies.We
judged that the majority of the studies had an unclear risk of
bias for most criteria; Figure 3 presents the overall risk of bias.
The characteristics of individual studies are summarised in the
Characteristics of included studies tables. We did not downgrade
the quality of the evidence for unclear risk of bias.
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Figure 2. Funnel plot of comparison: 1 Primary analysis, outcome: 1.1 Catheter-related blood stream
infection.
16Dressings and securement devices for central venous catheters (CVC) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
17Dressings and securement devices for central venous catheters (CVC) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Nine of the 22 included studies described an adequate method
of sequence generation (Arvaniti 2012; Garland 2001; le Corre
2003; Levy 2005; Nikoletti 1999; Olson 2004; Timsit 2009;
Timsit 2012; Yamamoto 2002). An adequate method of allocation
concealment was reported in only two of the studies (Garland
2001; Yamamoto 2002).
Blinding
No study blinded personnel or participants, as this was not achiev-
able due to the visibility of the intervention. Only six studies re-
ported blinding the outcome assessor (Arvaniti 2012; de Barros
2009; Nikoletti 1999; Ruschulte 2009; Timsit 2009; Timsit
2012).
Incomplete outcome data
Five studies provided incomplete outcome data with high percent-
ages of undescribed attrition and loss-to-follow up (Carrer 2005;
Conly 1989; leCorre 2003; Levy 2005;Roberts 1998). Seven stud-
ies reported complete outcome data (Arvaniti 2012; Giles 2002;
Hill 2010; Pedrolo 2011; Ruschulte 2009; Timsit 2009; Timsit
2012). The remaining studies provided inadequate information
to ascertain attrition bias.
Selective reporting
Protocols were available for two studies that had been registered
in clinical trial registries (Timsit 2009; Timsit 2012). Five studies
did not provide some of their outcomes per interventional group
(Carrer 2005; Chambers 2005; Conly 1989; Olson 2004; Roberts
1998)
Other potential sources of bias
Five of the studies were sponsored by product manufactur-
ers (Garland 2001; Shivnan 1991; Timsit 2012; Wille 1993;
Yamamoto 2002). Three studies described systematic differences
between the intervention and control groups at baseline (Arvaniti
2012; Conly 1989; Hill 2010), while three studies provided no
participant baseline data, only CVC information (Hagerstrom
1994; Pedrolo 2011; Wille 1993). The majority of the included
RCTs randomised participants and not their CVCs. Two studies
recruited participants multiple times for multiple CVCs (Carrer
2005; Chambers 2005). One study stopped early for unknown
reasons (Olson 2004).
Effects of interventions
See: Summary of findings for the main comparison Gauze
and tape compared to standard polyurethane (SPU) for CVC
dressing and securement; Summary of findings 2 Chlorhexidine
gluconate-impregnated (CGI) dressing compared to SPU
dressings forCVCdressing and securement;Summary of findings
3 Medication-impregnated dressings compared to all other
dressing types for central venous catheter (CVC) dressing and
securement
The main results are displayed in Summary of findings for the
main comparison(gauze and tape compared with SPU), Summary
of findings 2 (CGI compared with SPU) and Summary of findings
3(medication impregnated dressings compared with all other
dressing types).
1.1 Incidence of catheter-related bloodstream
infection (BSI)
Analysis 1.1 displays the results of the meta-analysis for catheter-
related BSI for the pair-wise comparisons.
1.1.1 Gauze and tape compared with standard polyurethane
(SPU) dressings (eight trials, 506 participants)
Eight studies in adult bone marrow transplantation units (101),
haemodialysis (138), gastroenterological (72), adult ICU (21),
paediatric and adult oncology (98) and general ward (76) settings
reported this intervention and outcome, with 28 participants out
of a total of 506 developing a catheter-related BSI (Brandt 1996;
Conly 1989; de Barros 2009; Giles 2002; Hagerstrom 1994; le
Corre 2003; Pedrolo 2011; Shivnan 1991). There was no clear
difference between gauze and tape and SPU dressings on the in-
cidence of catheter-related BSI (RR 0.64, 95% CI 0.26 to 1.63;
Analysis 1.1). Low quality evidence (downgraded for inconsis-
tency and imprecision). Statistical heterogeneity was low but point
estimates cross the line (Chi² 6.82; P value 0.34; I² 12%).See
Summary of findings for the main comparison.
1.1.2 Gauze and tape compared with no dressings (one trial,
78 participants)
One small study in an adult oncology setting (Olson 2004) re-
ported on the effect of gauze and tape compared with no dressings
and found no clear difference in the incidence of catheter-related
BSI (RR 1.47, 95% CI 0.72 to 3.00) however this study was too
small to detect a difference should it exist. Low quality evidence
(downgraded for risk of bias and imprecision)
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1.1.3 SPU dressings compared with old generation SPU
dressings (one trial, 101 participants)
One small study in an adult surgical setting (Wille 1993) found
clear difference in the incidence of catheter-related BSI between
SPU dressings and “old generation” SPU dressings (RR 0.33, 95%
CI0.04 to 3.04) however because this studywas so small we cannot
be confident that a difference does not exist. Low quality evidence
(downgraded for imprecision)
1.1.4 Highly adhesive transparent dressing compared with
SPU dressings (one trial, 982 participants)
One study in an adult ICU setting (Timsit 2012) found no clear
difference in catheter-related BSI between a highly adhesive trans-
parent dressing and SPU dressings (RR 0.60, 95% CI 0.20 to
1.77). Moderate quality evidence (downgraded for imprecision)
1.1.5 Chlorhexidine gluconate-impregnated (CGI) dressings
compared with SPU dressing (five trials, 4876 participants)
We pooled five trials (Arvaniti 2012; Garland 2001; Ruschulte
2009; Timsit 2009; Timsit 2012) comparingCGIwith SPUdress-
ings. It is unclearwhetherCGIdressings reduce the risk of catheter-
related BSI compared with SPU dressings as although there was
a reduction in risk of catheter-related BSI this did not reach tra-
ditional levels of statistical significance (P=0.08) (RR 0.65, 95%,
CI 0.40 to 1.05; Analysis 1.1.2) (moderate quality evidence, down-
graded for imprecision). Five studies in adult ICU (3620), neona-
tal ICU (705) and adult haematology/oncology (601) units/wards
reported this intervention and outcome, with 106 participants out
of 4876 developing a catheter-related BSI . Statistical heterogene-
ity was low (Chi² 5.38; P value 0.25; I² 26%). See Summary of
findings 2.
1.1.6 CGI dressing compared with highly adhesive
transparent dressing (one trial, 1453 participants)
One study (adult ICU) found no clear difference in the incidence
of catheter-related BSI (Timsit 2012) between CGI dressings and
a highly adhesive transparent dressing (RR 0.48, 95% CI 0.14 to
1.66). Moderate quality evidence (downgraded for imprecision)
1.1.7 SPU dressings compared with hydrocolloid dressings
(one trial, 128 participants)
There were fewer cases of catheter-related BSI with SPU dress-
ings than hydrocolloid dressings in a single study in adult ICU
(Nikoletti 1999) (RR 0.53, 95% CI 0.29 to 0.97). Moderate qual-
ity evidence (downgraded for imprecision)
1.1.8 SPU dressings compared with sutureless securement
devices (one trial, 170 participants)
There were fewer cases of catheter-related BSI with sutureless se-
curement devices than SPU in a single study in adult general acute
and home care settings (Yamamoto 2002) (RR 8.00, 95% CI 1.02
to 62.58, P value 0.05). Low quality evidence (downgraded for risk
of bias and imprecision).
1.1.9 CGI dressing compared with no dressing (one trial, 112
participants)
There was no clear difference in the incidence of catheter-related
BSI between CGI dressings and no dressing in one small study
(RR 0.27, 95% CI 0.06 to 1.22). This study was based in an adult
haematology setting (Chambers 2005). Moderate quality evidence
(downgraded for imprecision)
1.1.10 Medication-impregnated dressings compared with all
others (six trials, 5687 participants)
Six studies from adult ICU (4269), neonatal ICU (705) and adult
haematology/oncology (713) settings reported this intervention
and outcome; 124 participants out of a total of 5687 developed
a catheter-related BSI (Arvaniti 2012; Chambers 2005; Garland
2001; Ruschulte 2009; Timsit 2009; Timsit 2012). There was high
quality evidence that medication-impregnated dressings reduce the
risk of catheter-related BSI compared with all other dressings (RR
0.60, 95%CI 0.39 to 0.93; P value 0.02) (Analysis 1.1). Statistical
heterogeneity was low (Chi² 6.21; P value 0.29; I² 19%). See
Summary of findings 3.
1.2 Frequency of catheter-related bloodstream
infection per 1000 patient days
Analysis 1.2 presents the results of the meta-analysis for catheter-
related BSI per 1000 patient days for the pair-wise comparisons.
1.2.1 Gauze and tape compared with SPU dressings (two
trials, 8538 patient days)
Two studies in haemodialysis settings reported this intervention
and outcome, with 10 participants out of a total of 8538 patient
days developing a catheter-related BSI (de Barros 2009; le Corre
2003). There was no clear evidence of a difference in the frequency
of catheter -related BSI per 1000 patient days when gauze and
tape was compared with SPU dressing (RR 0.71, 95% CI 0.20 to
2.52; Analysis 1.2). . Statistical heterogeneity was low (Chi² 0.37;
P value 0.54; I² 0%). Moderate quality evidence (downgraded for
imprecision)
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1.2.2 SPU compared with old generation SPU (one trial, 780
patient days)
There was no clear difference in the frequency of catheter-related
BSI per 1000 patient days in a single study in an adult surgical
setting (Wille 1993) when SPUwas compared with old generation
SPU (RR 0.35, 95% CI 0.01 to 18.61). Moderate quality evidence
(downgraded for imprecision)
1.2.3 SPU compared with sutureless securement devices
(one trial, 5730 patient days)
One study in general adult acute and home settings (Yamamoto
2002) found no difference between SPU and sutureless secure-
ment devices in the frequency of catheter-related BSI per 1000
patient days (RR 0.13, 95%CI 0.00 to 5.82). Low quality evidence
(downgraded for risk of bias and imprecision)
1.2.4 CGI dressings compared with SPU (four trials, 42,689
patient days)
The pooled results of four studies (in adult ICU; 32,958 patient
days) and haematology/oncology; 9731 patient days) (Arvaniti
2012; Ruschulte 2009; Timsit 2009; Timsit 2012) show that CGI
dressings reduce the frequency of catheter-related BSI per 1000
patient days compared with SPU (RR 0.51, 95% CI 0.33 to 0.78,
P value 0.002; Analysis 1.2). There was no statistical heterogene-
ity detected (Chi² 2.52; P value 0.47; I² 0%). Moderate quality
evidence (downgraded for imprecision)
1.2.5 Highly adhesive transparent dressing compared with
SPU (one trial, 8831 patient days)
One study in adult ICU (Timsit 2012) found no difference in the
frequency of catheter-related BSI per 1000 patient days between
highly adhesive transparent dressings and SPU (RR 0.67, 95% CI
0.14 to 3.11). Moderate quality evidence (downgraded for impre-
cision)
1.2.6 CGI dressings compared with no dressing (one trial,
12,351 patient days)
One study in adult haematology (Chambers 2005) found no dif-
ference in the frequency of catheter-related BSI per 1000 patient
days between CGI dressings and no dressing (RR 3.98, 95% CI
0.76 to 20.91). Low quality evidence (downgraded for risk of bias
and imprecision)
1.3 Incidence of catheter tip colonisation
Analysis 1.3 displays the results of the meta-analysis for catheter
tip colonisation for the pair-wise comparisons.
1.3.1 Gauze and tape compared with SPU dressings (five
trials, 341 participants)
Five studies in haemodialysis (66), gastroenterological (72), adult
ICU (127), and general ward (76) settings reported this interven-
tion and outcome, with 99 participants out of a total of 341 hav-
ing their CVC tip colonised (Carrer 2005; Conly 1989; de Barros
2009; Giles 2002; Pedrolo 2011). There was no clear difference in
the risk of catheter tip colonisation between gauze and tape and
SPU dressings (RR 0.95, 95% CI 0.51 to 1.77; Analysis 1.3). .
See Summary of findings for the main comparison. Statistical het-
erogeneity was high (Chi² 12.06; P value 0.02; I² 67%). Very low
quality evidence (downgraded for inconsistency, indirectness and
imprecision)
1.3.2 CGI compared with SPU dressings (six trials, 4431
participants)
Pooling the results of six trials (Chi² 6.41; P value 0.27; I² 22%)
showed that the risk of catheter tip colonisation is reduced with
CGI compared with SPU dressings (RR 0.58, 95% CI 0.47 to
0.73; Analysis 1.3). Six studies reported this intervention and out-
come, with 457 participants out of a total of 4431 having their
CVC tip colonised (Arvaniti 2012; Garland 2001; Levy 2005;
Roberts 1998; Timsit 2009; Timsit 2012). These results are also
presented in Summary of findings 2. This analysis is based upon
participants from adult ICU (3581), neonatal ICU (705) and pae-
diatric ICU (145) settings. Moderate quality evidence (downgraded
for indirectness)
1.3.3 Highly adhesive transparent dressing compared with
SPU (one trial, 982 participants)
There was no difference in the incidence of catheter tip colonisa-
tion between highly adhesive transparent dressings and SPU (RR
1.32, 95% CI 0.88 to 1.98). This single study (Timsit 2012) was
in an adult ICU setting. Low quality evidence (downgraded for
imprecision and indirectness)
1.3.4 SPU compared with hydrocolloidal dressings (one trial,
128 participants)
One small study in adult ICU (Nikoletti 1999) found no differ-
ence in the incidence of catheter tip colonisation between SPU
and hydrocolloid dressings (RR 1.88, 95% CI 1.03 to 3.42). Low
quality evidence (downgraded for imprecision and indirectness)
1.4 Incidence of entry- and exit-site infections
1.4.1 Gauze and tape compared with SPU dressings (two
trials, 199 participants)
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The pooled results of two studies (Brandt 1996; Shivnan 1991)
comparing the use of gauze and tape with SPU dressings found no
clear difference in the incidence of entry- and exit-site infections
(RR 0.84, 95% CI 0.34 to 2.07; Analysis 1.4; (Chi² 0.15; P value
0.69; I² 0%). These studies took place in adult bone marrow trans-
plant unit (101) and paediatric and adult oncology (98) settings.
Moderate quality evidence (downgraded for imprecision)
1.4.2 SPU compared with CGI dressings (one trial, 33
participants)
A single small study in adult ICU (Roberts 1998) found no clear
difference in the incidence of entry- and exit-site infections be-
tween SPU and CGI dressings (RR 0.80, 95% CI 0.21 to 3.02).
Low quality evidence (downgraded for risk of bias and imprecision)
1.4.3 CGI dressings compared with no dressing (one trial,
112 participants)
A single small study in an adult haematology setting (Chambers
2005) found fewer entry- and exit-site infections with CGI than
with no dressing (RR 0.20, 95% CI 0.06 to 0.66). Low quality
evidence (downgraded for risk of bias and imprecision)
1.5 Incidence of skin or site colonisation
1.5.1 Gauze and tape compared with SPU dressings (two
trials, 170 participants)
Two studies (Giles 2002; Shivnan 1991).compared gauze and tape
with SPU in gastroenterology (72) and paediatric and adult on-
cology (98) settings. These studies were pooled ( I² 0%). There
was no difference In the incidence of skin or site colonisation be-
tween gauze and tape and SPU dressing (RR 0.86, 95% CI 0.30
to 2.51; Analysis 1.5). Moderate quality evidence (downgraded for
imprecision)
1.6 Incidence of skin irritation or damage
1.6.1 Gauze and tape compared with SPU dressings (one
trial, 21 participants)
There was no clear evidence of difference in skin irritation or
damage between gauze and tape and SPU in a single study (adult
ICU) (Pedrolo 2011) (RR 6.60, 95% CI 0.95 to 45.75). Moderate
quality evidence (downgraded for imprecision)
1.6.2 CGI compared with SPU (two trials, 850 participants)
There was no clear evidence of a difference in the incidence of skin
irritation or damage between CGI dressings and SPU when two
studies were pooled (Chi² 2.17; P value 0.14; I² 54%) (Garland
2001; Levy 2005) (RR 11.17, 95% CI 0.84 to 149.48; Analysis
1.6). These studies took place in neonatal ICU (705) and paedi-
atric ICU (145) settings. Higher rates of skin irritation or dam-
age were evidence in the neonatal than the paediatric population.
Moderate quality evidence (downgraded for imprecision)
1.6.3 SPU compared with other medication-impregnated
dressings (one trial, 118 participants)
A single small study (Hill 2010) compared the effects of SPU and
other medication-impregnated dressings, in this case silver, on the
rate of skin irritation or damage in neonatal ICU and found no
difference (there was no irritation or skin damage in either group).
Low quality evidence (downgraded for imprecision)
1.6.4 SPU compared with sutureless securement devices
(SSD; one trial, 170 participants)
A single small study (Yamamoto 2002) found no difference in the
incidence of skin irritation or damage between SPU and SSDs in
general adult acute and home-care settings. (RR 0.61, 95% CI
0.06 to 5.78). Low quality evidence (downgraded for risk of bias
and imprecision)
1.7 Incidence of failed catheter securement
1.7.1 Gauze and tape compared with SPU dressing (two
trials, 167 participants)
The pooled results of two studies (Brandt 1996; de Barros 2009)
found no difference between gauze and tape and SPU dressings
in the incidence of failed catheter securement (RR 0.90, 95% CI
0.33 to 2.49; Analysis 1.7). This analysis is based upon partici-
pants from adult BMT (101) and haemodialysis (66) settings. Sta-
tistical heterogeneity was absent (Chi² 0.54; P value 0.46; I² 0%).
Moderate quality evidence (downgraded for imprecision)
1.7.2 SPU compared with CGI dressings (one trial, 306
participants)
One study in adult ICU (Arvaniti 2012) compared SPU with
CGI dressings and found no difference in the incidence of failed
catheter securement (RR 2.40, 95% CI 0.47 to 12.20). Moderate
quality evidence (downgraded for imprecision)
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1.7.3 SPU compared with SSD (one trial, 170 participants)
One study in adult acute and home care settings compared
(Yamamoto 2002) SPU with SSD and found no difference in the
incidence of failed catheter securement (RR 1.20, 95% CI 0.55
to 2.63). Low quality evidence (downgraded for risk of bias and
imprecision)
1.8 Dressing condition or durability
1.8.1 Gauze and tape compared with SPU dressing (one
trial, 21 participants)
One very small study in adult ICU (Pedrolo 2011) compared gauze
and tape with SPU and found no difference in dressing condition
or durability (RR 0.57, 95% CI 0.10 to 3.27). Moderate quality
evidence (downgraded for imprecision)
1.9 Mortality
1.9.1 Gauze and tape compared with SPU dressing (one
trial, 21 participants)
One very small study in adult ICU (Pedrolo 2011) comparedmor-
tality in people receiving either gauze and tape or SPU and found
no clear difference (RR 1.10, 95% CI 0.19 to 6.41). Moderate
quality evidence (downgraded for imprecision)
1.9.2 SPU compared with CGI dressing (one trial, 606
participants)
One study in adult ICU (Arvaniti 2012) an increase in mortality
with SPU compared with CGI dressing (RR 3.71, 95%CI 2.48 to
5.55). This study had a high mortality rate, with a total of 80 out
of 606 participants dying. Moderate quality evidence (downgraded
for imprecision)
1.9.3 SPU dressing compared with other medication-
impregnated dressing (one trial, 118 participants)
One study in neonatal ICU (Hill 2010) found no clear differ-
ence in mortality between SPU and other medication-impreg-
nated dressings (impregnated with silver) (RR 1.53, 95% CI 0.14
to 16.31). Low quality evidence (downgraded for risk of bias and
imprecision)
1.9.4 CGI compared with no dressing (one trial, 112
participants)
One study in adult haematology (Chambers 2005) found no clear
difference in mortality between CGI and no dressing (RR 1.33,
95% CI 0.55 to 3.25). Low quality evidence (downgraded for risk
of bias and imprecision)
Sensitivity analyses
We planned sensitivity analyses for two major outcomes, catheter-
related BSI and catheter tip colonisation, to evaluate the impact of
excluding studies based on the risks of selection and attrition bias.
We were unable to perform the analyses on catheter-related BSI,
as poor reporting meant we were not able to identify those studies
at high risk bias. We performed sensitivity analyses on catheter
tip colonisation, for the comparison of CGI dressings versus SPU.
There were insufficient studies for the other comparisons to permit
a meaningful analysis to be performed.
2.1 Catheter tip colonisation
As described in Analysis 2.1, the exclusion of two studies (Levy
2005; Roberts 1998) with a high risk of attrition bias did not
alter the pooled estimates substantially when we compared CGI
dressings with SPU (’without’ attrition bias: RR 0.59, 95% CI
0.46 to 0.77, compared to ’with’ attrition bias: RR 0.58 95% CI
0.47 to 0.73).
Multiple treatments meta-analysis
We undertook a multiple treatments meta-analysis for each out-
come for which more than two interventions were compared.
These results are summarised graphically in the figures section.
3.1 Incidence of catheter-related BSI
SSD had the highest probability of being the most effective inter-
vention to reduce the incidence of catheter-related BSI, followed
by CGI (Figure 4). Low quality of evidence (downgraded due to
moderate risk of bias, likely inconsistency and moderate common
heterogeneity).
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Figure 4. .1 MTM Network plot: Incidence of catheter related bloodstream infectionSPU standard
polyurethane, G+T gauze and tape, BPU bordered polyurethane, CGI chlorhexidine gluconate impregnated,
NOD no dressing, SSD sutureless securement device, OLD old standard polyurethane, HAD highly adhesive
dressing.
3.2 Frequency of catheter-related BSI per 1000 patient days
“Old” SPU had the highest probability of being the most effective
intervention to reduce the frequency of catheter-related BSI per
1000 patient days, followed by CGI (Figure 5). Moderate quality
of evidence (downgraded due to moderate risk of bias).
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Figure 5. 3.2 MTM Network plot: Frequency of catheter-related bloodstream infection per 1000 patient
daysSPU standard polyurethane, G+T gauze and tape, CGI chlorhexidine gluconate impregnated, NOD no
dressing, OLD old standard polyurethane, HAD highly adhesive dressing.
3.3 Incidence of catheter tip colonisation
CGI had the highest probability of being the most effective inter-
vention to reduce the incidence of catheter tip colonisation, fol-
lowed by gauze and tape (Figure 6). Moderate quality of evidence
(downgraded due to moderate risk of bias).
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Figure 6. 3.3 MTM Network plot: Incidence of catheter tip colonisationSPU standard polyurethane, G+T
gauze and tape, CGI chlorhexidine gluconate impregnated, HYD hydrocolloid, HAD highly adhesive dressing.
3.4 Incidence of entry- or exit-site infection
Gauze and tape had the highest probability of being the most
effective intervention to reduce the incidence of entry or exit site
infection. No dressing had the lowest probability (Figure 7). Low
quality of evidence (downgraded due to moderate risk of bias and
low levels of transitivity (indirectness)).
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Figure 7. 3.4 MTM Network plot: Incidence of entry- and exit- site infectionsSPU standard polyurethane,
G+T gauze and tape, CGI chlorhexidine gluconate impregnated, NOD no dressing.
3.5 Incidence of skin irritation or damage
SSD had the highest probability of being the most effective inter-
vention to reduce the incidence of skin irritation or damage, fol-
lowed by SPU (Figure 8). Low quality of evidence (downgraded due
to moderate risk of bias, moderate heterogeneity (inconsistency)).
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Figure 8. 3.5 MTM Network plot: Incidence of skin irritation or damageSPU standard polyurethane, G+T
gauze and tape, CGI chlorhexidine gluconate impregnated, SSD sutureless securement device, OTH other
medication impregnated dressing
3.6 Incidence of failed catheter securement
Gauze and tape had the highest probability of being the best in-
tervention to reduce the incidence of failed catheter securement,
followed by SPU (Figure 9). Moderate quality of evidence (down-
graded for moderate risk of bias).
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Figure 9. 3.6 MTM Network plot: Incidence of failed catheter securementSPU standard polyurethane, CGI
chlorhexidine gluconate impregnated, SSD sutureless securement device,
3.7 Incidence of mortality
Nodressingwas associatedwith the highest probability of being the
most effective intervention to reduce mortality, followed by CGI
(Figure 10). Low quality of evidence (downgraded formoderate risk
of bias, low levels of transitivity (indirectness)).
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Figure 10. 3.7 MTM Netowrk plot: MortalitySPU standard polyurethane, G+T gauze and tape, CGI
chlorhexidine gluconate impregnated, NOD no dressing, OTH other medication impregnated dressing
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Chlorhexidine gluconate- impregnated (CGI) impregnated dressings compared to SPU dressing for central venous catheter (CVC) securement and dressing
Patient or population: pat ients with CVCs
Setting: all sett ings
Intervention: CGI dressing
Comparison: SPU dressings
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with SPU dress-
ings
Risk with Chlorhex-
idine gluconate- im-
pregnated (CGI) dress-
ing
Catheter-related blood
stream infect ion
assessed with: as de-
f ined by criteria spec-
if ied by Maki 2006;
Mermel 2009 and
O’Grady 2002
Study populat ion RR 0.65
(0.40 to 1.05)
4876
(5 RCTs) MODERATE 1
30 per 1000 19 per 1000
(12 to 31)
Moderate
18 per 1000 12 per 1000
(7 to 19)
Catheter t ip colonisa-
t ion:
assessed with: posit ive
semi-quant itat ive (>15
cfu/ catheter segment‘‘
or quant itat ive (>10 3
cfu/ catheter segment’’
culture f rom a proximal
or distal catheter seg-
ment (O’Grady 2002)
Study populat ion RR 0.58
(0.47 to 0.73)
4431
(6 RCTs) MODERATE 2
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147 per 1000 85 per 1000
(69 to 108)
Moderate
268 per 1000 155 per 1000
(126 to 196)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to low rate of events and wide 95% conf idence intervals
2 Downgraded due to outcome being a surrogate measure of catheter-related bloodstream infect ion
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Medicat ion-impregnated dressings compared with all other dressing types for CVC dressing and securement
Patient or population: pat ients with CVCs
Setting: all sett ings
Intervention: medicat ion-impregnated dressings
Comparison: all other dressing types
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with all other
dressing types
Risk with M edication-
impregnated dressings
Catheter-related blood
stream infect ion
assessed with: as de-
f ined by criteria spec-
if ied by Maki 2006;
Mermel 2009 and
O’Grady 2002
Study populat ion RR 0.60
(0.39 to 0.93)
5687
(6 RCTs) HIGH
28 per 1000 17 per 1000
(11 to 26)
Moderate
64 per 1000 38 per 1000
(25 to 59)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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D I S C U S S I O N
Summary of main results
CGI dressings may reduce catheter-related blood stream infection
relative to SPU and other dressings (moderate quality of evidence).
This directionof effect is consistent for the outcomes of relative risk
of catheter-related blood stream infection, rates of blood stream
infection per 1000 patient days and catheter tip colonisation how-
ever there is uncertainty around the result for the primary outcome
of relative risk and no difference cannot be excluded. There is high
quality evidence that the use of medication-impregnated dressing
products reduce the incidence of catheter-related BSI in compari-
son with all other dressing types. The class of interventions termed
’medication-impregnated dressings’ included only CGI dressings
in various forms (e.g. patch or whole dressing), whilst the ’all other
dressing types’ group involved SPU, highly adhesive transparent
dressings and no dressing. There was moderate quality evidence
for a reduction in the frequency of catheter-related BSI per 1000
patient days with the use of CGI dressings, compared to SPU.
There was also moderate quality evidence in the reduction in the
risk of colonisation of the CVC tip with CGI dressings compared
to SPU. Colonisation of the CVC tip is considered an indirect
measure of catheter-related BSI. Most studies were conducted in
ICU settings (Analysis 1.1.2: 89% participants; Analysis 1.2.2:
77% catheter days; Analysis 1.3.2: 100% participants). The evi-
dence for the effectiveness of CGI dressings is probably not gen-
eralisable beyond these settings.
The results of the multiple-treatment meta-analysis (MTM) are
generally in agreement with the pair-wise comparisons. CGI dress-
ings were ranked as having the highest probability of reducing
the incidence of catheter tip colonisation and second to SSD for
reducing the incidence of catheter-related BSI and frequency of
catheter-related BSI per 1000 patient days. The level of evidence
reported in the MTM was of low to moderate quality, and further
research may alter these results.
One large RCT comparing CGI and SPU dressings was excluded
from this review (Maki 2000; 1401 participants); this RCT com-
pared the effectiveness of CGI dressings with SPU for the secure-
ment and dressing of arterial catheters, pulmonary artery catheters
and CVC. The trial found a significant reduction in the incidence
of catheter-related BSI for participants receiving CGI dressings (P
value < 0.05). This study was excluded because the outcome data
were not provided separately for catheter type. We contacted the
study authors, but they were not able to provide us with the CVC
outcomes. Exclusion of these results may have had a significant
impact on the results of the meta-analyses included in this review.
If we had been able to include these data, it is highly likely that our
estimates of effect for the incidence of catheter-related BSI would
have become significant and favoured CGI dressings compared to
SPU.
There is some concern in the current literature regarding the in-
creased risk of skin irritation or damage for CGI dressings. Our
current analysis results were heavily influenced by a single study
that examined 705 neonatal ICU participants (59.2% of partic-
ipants in the meta-analysis; Garland 2001). The majority of re-
actions occurred in neonates up to 28 weeks gestational age and
up to 1000 g in weight. Local contact dermatitis from the CGI
dressing may limit its use in acutely ill low-birthweight neonates
or others with impaired skin integrity (Garland 2001).
Overall completeness and applicability of
evidence
We identified a large number of studies in which the population,
intervention, comparison and outcomes matched our prespeci-
fied selection criteria. The studies were conducted in 25 different
countries, in a range of settings and age-related populations, with
different CVC types. Despite this, the majority of dressing and
securement products have not been adequately compared, due to
the large variety that are currently available. This means that there
is ongoing uncertainty regarding the effectiveness of several of the
commercially and clinically available products. Additionally, sev-
eral of our outcomes, that reported on skin or site colonisation
and dressing durability, were poorly reported. CVC catheter secu-
rity was not adequately addressed by the included studies. Con-
sidering the serious consequences associated with accidental CVC
removal due to poor security, this is an outcome that needs to be
investigated.
Quality of the evidence
Risk of bias was difficult to assess in most studies because of poor
reporting. Since it was not possible to blind personnel or partic-
ipants to the CVC dressing and securement product, there was
a potential source of performance bias and staff or patients may
have behaved differently given knowledge of the intervention; this
seems unlikely however. Blinding of outcome assessors was feasi-
ble for the primary outcome, but was achieved and reported ade-
quately by only six of the studies (Arvaniti 2012; de Barros 2009;
Nikoletti 1999; Ruschulte 2009; Timsit 2009; Timsit 2012).Only
two studies achieved and reported the minimisation of selection
bias adequately via both random sequence generation and allo-
cation concealment (Garland 2001; Yamamoto 2002). Several of
the trials reported receiving partial or full manufacturer sponsor-
ship (Garland 2001; Shivnan 1991; Timsit 2012; Wille 1993;
Yamamoto 2002), however it is unclear whether this had an im-
pact on the reported results. It is common within the field of in-
travascular device research for investigators to receive partial or full
sponsorship for the completion of research. The funnel plot did
not reveal any underlying positive or negative publication bias.
Potential biases in the review process
We followed clearly described procedures to prevent potential
bias in the review process. The comprehensive search of multiple
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sources and themethodswe used are transparent and reproducible.
Claire Rickard and Amanda Ullman have received research fund-
ing from Centurion Medical Products (Williamston, MI) that is
unrelated to this review; products manufactured by Centurion
Medical Products are not included within this review. The other
review authors have not reported any conflict of interest.
Agreements and disagreements with other
studies or reviews
The previous version of this review ’Gauze and tape and
polyurethane dressings for CVC’ identified a four-fold increase
in the rate of catheter-related BSI when a polyurethane dressing
was used, compared with gauze and tape (Webster 2011). How-
ever, with the widening of the inclusion criteria to include recently
published research and participants in community settings, this
difference has ceased to be significant.
The Centres for Disease Control and Prevention (CDC) recom-
mend the use of either a sterile gauze or SPU dressing to cover the
CVC site (O’Grady 2011). By comparison, ’epic3’, the English
national evidence-based guidelines (Loveday 2014), recommend
the use of SPU, unless the insertion site is perspiring profusely
or the insertion site is bleeding or leaking. Both the CDC and
epic3 guidelines advocate the use of a CGI dressing as a strategy
to reduce catheter-related BSI, but CDC recommend CGI dress-
ings only for temporary short-term catheters in patients over two
months of age and then only if the central line-associated BSI rate
is not decreasing despite adherence to basic prevention methods.
Our review suggests that catheter-related BSI may be reduced with
CGI compared with SPU, and that the risk of catheter-related BSI
is reduced with medication-impregnated dressings compared with
all others. Additionally, we identified a reduction in the incidence
of catheter tip colonisation when using a CGI dressing compared
to SPU. A previous meta-analyses, Ho 2006, that compared the
effectiveness of CGI dressings to SPU for intravascular and epidu-
ral catheters had similar results. That meta-analysis identified a
significant reduction in intravascular catheter or exit-site bacterial
colonisation for CGI dressings compared to SPU (14.8% versus
26.9%; odds ratio (OR) 0.47, 95% CI 0.34 to 0.65; P value <
0.00001) and a trend towards a reduction in intravascular catheter-
related BSI or central nervous system infection (2.2%versus 3.8%;
OR 0.58, 95% CI 0.29 to 1.14; P value 0.11). Participants who
had their intravascular and epidural catheters dressed with a CGI
dressing had a significantly increased rate of local cutaneous reac-
tions in comparison to those dressed with SPU (OR 8.17, 95%CI
1.19 to 56.14, P value 0.04), and the majority of these reactions
occurred in neonatal patients.
A recent meta-analysis, Safdar 2014, evaluated the efficacy of
CGI dressing compared to ’conventional’ dressings for CVC, pul-
monary artery or peripheral arterial catheters. This analysis iden-
tified that the use of a CGI dressing compared to a ’conventional’
dressing reduced the risk of catheter-related BSI (RR 0.60, 95%
CI 0.41 to 0.88; P value 0.009) and catheter colonisation (RR
0.52, 95% CI 0.43 to 0.64; P value < 0.001). These results agree
with this review, even with the inclusion of pulmonary artery and
arterial catheters, in addition to CVC.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is some evidence that chlorhexidine-impregnated (CGI)
dressings used for securing central venous cathetersmay reduce the
risk of catheter-related BSI, compared with standard polyurethane
(SPU) dressings and other (non-impregnated) dressing types. This
evidence mainly comes from intensive care unit settings.
The evidence for the relative effects of different dressing and se-
curement comparisons, including gauze and tape versus SPU, on
catheter tip colonisation and catheter-related BSI is unclear.
There was inadequate research to permit us to make recommen-
dations about CVC security using the different dressing and se-
curement products.
Implications for research
More, high quality research is needed regarding the relative effects
of dressing and securement products for CVCs. New products
are continually becoming commercially available, and researchers
need to provide the evidence to inform clinical decision making in
this area. Clinically important outcomes including CVC security,
have not been adequately addressed by current research.
Future research may adjust the estimates of effect for the products
included in this review. Researchers should plan their protocols
so that the risk of bias in each domain is minimised and should
report trials clearly in accordance with the CONSORT guidelines
(Schulz 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arvaniti 2012
Methods RCT in 5 ICUs in Greece
Participants 306 participants admitted to ICUs requiring a multilumen CVC
Inclusion criteria:
• CVC predicted to stay in ICU patient for ≥ 3 days
• first CVC in ICU
Exclusion criteria:
• < 18 years
• neutropenic patients
• pregnant women
• patients with an expected ICU stay of < 3 days
• known allergy to silver or chlorhexidine
Interventions Group I: SPU changed every 3 days or sooner if spoiled or contaminated
Group II: SPU and a chlorhexidine-impregnated sponge (BiopatchTM ) changed every
7 days
Both groups had sterile gauze over the entry site for the first 24 hours
Outcomes • Catheter-related BSI
• Catheter-tip colonisation
• Catheter security
• Mortality
Notes Group III: Additional 159 participants not included in the review: silver-impregnated
CVC (OligonTM ) due to co-intervention.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “patients were randomly allocated to one of the
three groups, separately for each participating ICU, and ac-
cording to computer-generated randomization sequences”
(p 421)
Allocation concealment (selection bias) Unclear risk Quotation: “The randomization number and the corre-
sponding study group were sealed in envelopes in numeric
order. Envelopes were posted to the ICUs with accompany-
ing instructions to be opened by respecting their numerical
order” (p 421)
Not stated if envelopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “Double-blind design was not possible as a re-
sult of apparent differences between the compared prod-
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Arvaniti 2012 (Continued)
ucts” (p 421)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotation: “Two ICU infectious diseases experts scruti-
nized all data blinded to the randomization group to iden-
tify concomitant infections and avoid erroneous attribu-
tion of the recorded events to the study catheters” (p 422)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Well described attrition data; loss to follow up for catheter
tip colonisation outcome 19.1% (figure 1; p 422)
Intention-to-treat analysis undertaken. Quotation: “data
were also analyzed as per protocol analysis in which all
uncultured catheters were considered missing” (p 422)
Selective reporting (reporting bias) Unclear risk No clinical trial registration or published protocol
All outcomes reported as described in publication
Other bias Unclear risk Significant difference between groups for patient age (p
423)
Brandt 1996
Methods RCTl in the USA
Participants 101 participants undergoing autologous BMT with newly inserted long-term triple-
lumen, tunnelled HickmanT M CVCs
Inclusion criteria:
• > 18 years old
• alert, orientated, able to give informed consent
• admitted to the BMT unit for autologous BMT
• surgical insertion of a long-term CVC in the operating room
Exclusion criteria:
• pre-existing bacteraemia or fungaemia within 14 days of study entry
• CVC placement was intended to be short-term
Interventions Group I: SPU (Opsite 3000T M ; Smith andNephew)moisture vapour permeable dressing
changed every 7 days
Group II: sterile gauze with tape changed daily
Outcomes • Catheter-related BSI
• Entry- and exit-site infection
• Failed catheter security
Notes Dressing condition/durability reported: did not use a tool with established validity and
reliability
Risk of bias
Bias Authors’ judgement Support for judgement
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Brandt 1996 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quotation: “subjects were randomly assigned” (p 830)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No loss to follow-up reported. Less than 10% attrition. Not
stated whether intention-to-treat analysis was used
Selective reporting (reporting bias) Unclear risk No clinical trial registration or published protocol
Other bias Unclear risk Baseline balance of groups: no statistically significant differences
(p 832)
Carrer 2005
Methods Randomised, factorial controlled trial in a single Italian ICU
Participants 82 participants admitted to a medical-surgical ICU
Inclusion criteria:
• non-tunnelled CVC
• predicted dwell time of > 72 hours
Exclusion criteria: not reported
Interventions Group I: gauze and tape with low sterile barrier
Group II: transparent simple polyurethane (SPU) with low sterile barrier
Group III: gauze and tape with maximum sterile barrier
Group IV: SPU with maximum sterile barrier
For the purposes of the review: Groups I and III (gauze) were combined and Groups II
and IV (SPU) were combined
Outcomes Skin/site colonisation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Carrer 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not reported
Quotation: “patients were randomly subdi-
vided in four groups” (p 198)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Large attrition rate in some groups, which
are not accounted for in analysis. Intention-
to-treat analysis not used
Selective reporting (reporting bias) High risk Catheter-related BSI: information col-
lected, but not presented by intervention
group
Other bias Unclear risk Baseline balance of groups: Quotation:
“Groups were homogenous” (p 199)
Multiple CVCs per participant recruited,
analysis per CVC
Chambers 2005
Methods RCT in a single site in New Zealand
Participants 95 participants admitted to a haematology unit
Inclusion criteria:
• admitted to a haematology unit and undergoing chemotherapy
• tunnelled, cuffed CVC
• adult
Exclusion criteria:
• unable to give informed consent
• known allergy to chlorhexidine
Interventions Group I: no dressing
Group II: CGI dressings consisting of a 2.5 cm hydrophilic polyurethane foam disk con-
taining chlorhexidine gluconate in a sustained-release formulation, with a SPU (Opsite
IV3000T M ), changed weekly or as needed until catheter removal
Both groups had sterile gauze and SPU applied until the exit site was dry and free from
exudate
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Chambers 2005 (Continued)
Outcomes • Catheter-related BSI
• Entry- and exit-site infection
• Mortality
Notes Patients recruited more than once: CVC unit of analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “the clinical team was not blinded
to treatment” (p 59)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Quotation: “all cases of infection were initially
classified by three investigators (STC, RLS and
JS) and were later reviewed independently by
another investigator (PG)” (p 56)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Well described attritiondata: complete datawere
not available on 2 participants, 1 from each
group, who left the hospital and continued treat-
ment elsewhere (p 57). Intention-to-treat anal-
ysis described
Selective reporting (reporting bias) High risk No clinical trial registration or published proto-
col
Catheter tip colonisation not fully described per
study group
Other bias Unclear risk Minimal information of patient characteristics
described, not clear whether groups balanced at
baseline
Conly 1989
Methods RCT in a single site in Canada
Participants 79 participants admitted to medical, surgical, paediatric or ICU
Inclusion criteria:
• admitted to any medical, surgical or paediatric ward or ICU
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Conly 1989 (Continued)
• CVC inserted for a duration ≥ 3 days
Exclusion criteria:
• CVCs for short term haemodynamic monitoring
Interventions Group I: dry gauze and tape
Group II: SPU (OpsiteTM )
A pressure dressing was allowed for the first 24-48 hours for both groups
Outcomes • Catheter-related BSI
• Catheter tip colonisation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quotation: “were prospectively randomized”; “pa-
tients were randomly assigned by hospital number” (p
310)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Large amounts of attrition and missing data not ad-
equately described by the manuscript; including out-
come data
Selective reporting (reporting bias) High risk No clinical trial registration or published protocol
Skin/site colonisation not described by study group -
outcome could not be included in the review
Other bias High risk Groups not balanced at baseline including higher ICU
admission, steroid usage and jugular vein insertion in
the gauze group.Thismay have resulted in a higher risk
of catheter-related BSI and catheter tip colonisation
in this group
Patients recruited once, but multiple CVCs included.
CVC unit of analysis
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de Barros 2009
Methods RCT in Spain
Participants 66 participants with long-term CVCs for haemodialysis
Inclusion criteria:
• internal jugular CVC for haemodialysis treatment inserted by nephrologists
• end-stage renal disease
Exclusion criteria:
• acute renal failure undergoing dialysis via a femoral CVC
Interventions Group I: SPU (TegadermT M ; 3M) changed every 7 days or as needed
Group II: sterile gauze with tape changed at each dialysis session
Outcomes • Catheter-related BSI
• Catheter tip colonisation
• Failed catheter security
Notes One CVC per participant only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “a random list of dressings was used to divide 66
patients in two groups (33 in group 1 and 33 in group 2” (p
482)
Allocation concealment (selection bias) Unclear risk Quotation: “the sequences of dressings were kept in a locked
envelope. If the patient was eligible... the envelope containing
dressing sequences was opened and the following indicated in-
tervention was performed” (p 482)
Not reported whether the envelope was opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotation: “the microbiologists processed the samples without
knowing how patients were allocated in the study” (p 483)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No loss to follow-up reported. Not stated whether intention-to-
treat analysis was used
Selective reporting (reporting bias) Unclear risk No clinical trial registration or published protocol
Other bias Unclear risk Baseline balance of groups: no statistically significant differences
(p 484)
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Garland 2001
Methods RCT in 6 neonatal ICUs in the USA
Participants 705 participants admitted to a neonatal ICUs
Inclusion criteria:
• neonates who would likely require a CVC for at least 48 hours
• percutaneous and surgically inserted
Exclusion criteria: not clearly reported. Changed after 15 months of study recruitment
related to adverse reactions; infants < 26 weeks who required a CVC before 1 week of
age were excluded
Interventions Group I: SPU cleansed with 10% povidone iodine. Percutaneous CVC dressings were
changed every 7 days, surgically inserted CVC dressings were changed twice weekly
Group II: CGI dressing (BiopatchT M ) with 250 µg/mg of chlorhexidine gluconate and
SPU. Cleansed with 70% isopropyl. Both percutaneous and surgically inserted CVC
dressings were changed weekly
Outcomes • Catheter-related BSI
• Catheter-tip colonisation
• Skin irritation or damage: severe contact dermatitis
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “neonates were block randomized”
(p 1431)
Quotation: “computer generated randomiza-
tion codes developed by the study statisti-
cian were maintained by center pharmacists” (p
1432)
Allocation concealment (selection bias) Low risk Quotation: “maintained by the pharmacy at
hospital” (p 1432)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Similar attrition rates for loss to follow-up
in both groups; microbial analysis of catheter
colonisation not performed 8% of SPU group,
6% of CGI group
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Garland 2001 (Continued)
Selective reporting (reporting bias) Unclear risk Not registered as a clinical trial, no published
protocol
Reported all outcomes described in publication
Other bias Unclear risk Baseline balance of groups: no statistically sig-
nificant differences (table 1)
Confounding differences in interventions: 10%
povidone-iodine for skin antisepsis in Group I;
70% isopropyl for skin antisepsis in Group II
Funded by product company (Johnson and
JohnsonTM ) who manufacture the products
used in both intervention and control arms
Giles 2002
Methods RCT in a general surgery department in Turkey
Participants 72 participants with single-lumen polyurethane CVCs inserted pre-operatively
Inclusion criteria: not clearly outlined
Quotation: “patients undergoing surgical procedures for various benign or malignant
gastrointestinal disorders” (p 256)
Quotation: “the aims of CVC insertion were either for monitoring or TPN administra-
tion” (p 256)
Exclusion criteria: not reported
Interventions Group I: transparent occlusive dressing changed every 7 days unless signs of local in-
flammation
Group II: sterile gauze changed daily and insertion site cleaned by 10% povidone-iodine
solution
Outcomes • Catheter-related BSI
• Catheter tip colonisation
• Skin/site colonisation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Quotation: “according to the number pa-
tient on the random table” (p 256)
Allocation concealment (selection bias) Unclear risk Not reported
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Giles 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data. No loss to follow-up
Selective reporting (reporting bias) Unclear risk No registration of clinical trial or published
protocol. All reported outcomes described
Other bias Unclear risk Groups are balanced at baseline; no statisti-
cally significant difference between groups
Hagerstrom 1994
Methods RCT in Sweden in 2 dialysis units
Participants 14 participants with long-term CVCs for haemodialysis
Inclusion criteria:
• requiring haemodialysis treatment for renal insufficiency
Exclusion criteria: not reported
Interventions Group I: SPU (OpSite IV3000T M ) changed after haemodialysis procedure (approxi-
mately twice/week)
Group II: sterile gauze with tape changed after haemodialysis procedure (approximately
twice/week)
Outcomes Catheter-related BSI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “were randomised to one of the two
dressing treatment groups” (study design section)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
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Hagerstrom 1994 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition and loss to follow-up were not reported
Selective reporting (reporting bias) Unclear risk No registration of clinical trial or published proto-
col. All reported outcomes described
Other bias Unclear risk No description of baseline participant comparison
Hill 2010
Methods RCT in a neonatal ICU in the USA
Participants 100 participants admitted to a neonatal ICU
Inclusion criteria:
• admitted to neonatal ICU for at least 72 hours
• requiring a PICC to be placed
Exclusion criteria:
• CVC in situ, pre-existing skin condition or discolouration
Interventions Group I: SPU (TegadermT M ; 3M). Dressings changed every 3 weeks, unless otherwise
indicated
Group II: silver-impregnated dressing (Algidex Ag IV PATCHTM ) secured with a steri
strip. The patch, extraluminal catheter and exit sitewere then coveredwith a SPUdressing
(TegadermTM ; 3MM ). Dressings changed every 2 weeks, unless otherwise indicated
Outcomes • Skin irritation or damage: signs of redness, swelling or discolouration
• Mortality
Notes Catheter-related BSI was a secondary outcome of study, but was not defined
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “computer randomization” (p 471)
Allocation concealment (selection bias) Unclear risk Quotation: “envelopes containing the status were
assembled unknown to the principal investigator
and study nurse. After each patient was enrolled,
the envelope with the number corresponding to
order of enrolment was opened and the patient
was placed in their assigned group” (p 470)
Not stated if the envelopes were opaque
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Hill 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded. Quotation: “To assess skin safety,
the bedside nurse evaluated the skin under the
transparent dressing at least twice daily and doc-
umented any signs of redness, swelling or discol-
oration” (p 471)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded. Quotation: “To assess skin safety,
the bedside nurse evaluated the skin under the
transparent dressing at least twice daily and doc-
umented any signs of redness, swelling or discol-
oration” (p 471)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomedata adequately described.No reported
loss to follow-up
Selective reporting (reporting bias) Unclear risk No registration of clinical trial or published pro-
tocol. All reported outcomes described
Other bias High risk Baseline imbalances on several variables includ-
ing gender, age and birthweight
le Corre 2003
Methods RCT in Canada
Participants 58 participants with long-term CVCs for haemodialysis
Inclusion criteria:
• > 18 years old
• requiring haemodialysis treatment for chronic terminal renal insufficiency
• tunnelled jugular CVC inserted by vascular radiologist
• competent to provide informed consent
Exclusion criteria:
• receiving systemic antibiotic therapy
• history of bacteraemia within previous 3 months without change of CVC
Interventions Group I: SPU (TegadermT M ; 3M) changed every 7 days
Group II: sterile gauze with tape changed every 2-3 days
Outcomes Catheter-related BSI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “computer generated 1:1 ratio” (p 57)
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le Corre 2003 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “open-label” (p 57)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: “open-label” (p 57)
Incomplete outcome data (attrition bias)
All outcomes
High risk Large amount of attrition. Only 58/62 were included in final
analysis; intention-to-treat not used. 17 not followed up to re-
moval at 6 months
Selective reporting (reporting bias) Unclear risk Not registered as a clinical trial, no published protocol
Other bias Unclear risk Baseline balance of groups: no statistically significant differences
(table 1)
Levy 2005
Methods RCT in a single paediatric cardiac ICU in Israel
Participants 145 participants admitted to the paediatric cardiac ICU
Inclusion criteria:
• 0-18 years age
• Require a CVC for > 48 hours
• Inserted in an operating theatre by an anaesthetic specialist
Exclusion criteria: not reported
Interventions Group I: SPU (TegadermTM ; 3M) only changed when required (e.g. mechanical com-
plication, bleeding, oozing, signs of exit-site infection)
Group II: CGI (BiopatchT M ) and SPU only changed when required (e.g. mechanical
complication, bleeding, oozing, signs of exit-site infection)
Outcomes • Catheter tip colonisation
• Skin irritation or damage: contact dermatitis
Notes Catheter-related BSI: data collected as a secondary outcome, but study definition did
not match review definition
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Random number generator”
(p 677)
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Levy 2005 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded. Quotation: “The CVC inser-
tion site was inspected daily by the nursing
staff and by the study investigators (O.D.)
for adverse events” (p 677)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quotation: “the microbiology laboratory
personnel were blinded and could not iden-
tify which group the CVC had been ran-
domized” (p 677)
Skin irritation outcome assessor not
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Significant attrition and loss to follow-up.
Post-randomization attrition information
not provided by group
Selective reporting (reporting bias) Unclear risk No registration of clinical trial or published
protocol
Exit-site infection rates were not reported
in results section
Other bias Unclear risk Baseline balance of groups: no statistically
significant differences (p 678)
Nikoletti 1999
Methods RCT in an adult ICU in Australia
Participants 150 participants with CVCs inserted in ICU
Inclusion criteria:
• ≥ 18 years old
• insertion of a multilumen CVC in ICU
Exclusion criteria:
• CVC inserted for < 24 hours
• inserted outside ICU
• inserted via guidewire exchange
• tunnelled or implanted CVCs
Interventions Group I: SPU (TegadermT M ; 3M) changed every 5days or earlier if soiled or nonadherent
Group II: hydrocolloid dressing (ComfeelTM ) changed every 5 days or earlier if soiled
or nonadherent
Outcomes Catheter-tip colonisation
Notes Catheter-related BSI and skin colonisation outcomes were described, but did not meet
the review’s outcome definition
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Nikoletti 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described in publication
Correspondence with authors: “computer gener-
ated random numbers”
Allocation concealment (selection bias) Unclear risk Not reported in publication or correspondence
with authors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not described in publication
Correspondence with authors: “participants and
clinicians were not blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not described in publication
Correspondence with authors: “blinded microbio-
logical outcome assessment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Large amounts of missing data and attrition. The
majority was well described in the publication
Selective reporting (reporting bias) Unclear risk Protocol well described, but not published. Not
registered as a clinical trial
Other bias Low risk Baseline balance of groups: no statistically or clin-
ically significant differences in age, critical illness
severity, length of hospital stay (Table 2, p 491)
Olson 2004
Methods RCT in an inpatient and outpatient oncology setting in Canada
Participants 78 participants undergoing treatment for cancer
Inclusion criteria:
• 18-75 years old
• life expectancies of 6 months or more
• receiving their first CVC
• double or triple lumen CVC
• available for follow-up
• visually and cognitively competent
• able to read and write English
Exclusion criteria:not stated
Interventions Group I: sterile gauze dressing, changed daily if neutropenic or every second day if not
neutropenic; cleansed with 4% chlorhexidine in 70% alcohol
Group II: no dressing
Both groups were treated as if in Group I until day 21 post CVC insertion, when they
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Olson 2004 (Continued)
were randomised
Outcomes Catheter-related BSI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not stated in publication
Private correspondence with authors:
“computer generated sequence”
Allocation concealment (selection bias) Unclear risk Not stated in publication
Private correspondence with authors: “en-
velopes”, not stated if opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and family members cared for
the CVC dressing and securement regimen
throughout the study (p 38)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No attrition or loss-to-follow up data pro-
vided
Selective reporting (reporting bias) High risk Outcomes of catheter-tip colonisation and
skin/site colonisation were not reported
No clinical trial registration or published
protocol
Other bias Unclear risk Trial stopped recruitment early for un-
known reasons
Pedrolo 2011
Methods RCT in Brazil
Participants 21 participants admitted to ICU
Inclusion criteria:
• > 18 years
• non-tunnelled CVCs
• recruited within 24 hours of ICU admission or 8 hours of CVC insertion
Exclusion criteria: not reported
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Pedrolo 2011 (Continued)
Interventions Group I: SPU (TegadermTM ; 3M) changed every 7 days or when exudate or displacement
made it necessary
Group II: sterile gauze with tape changed daily
Outcomes • Catheter-related BSI
• Catheter tip colonisation
• Dressing condition durability defined: quotation: “fixation to the skin” (p 280)
• Skin irritation or damage: quotation: “local reaction to dressing was verified
through skin exfoliation, maceration and/or allergic reactions presented where the
selected material was in contact with the skin” (p 280)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “a drawing was performed to allocate individuals in
the control or study groups” (p 279)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: “all catheters were observed until removed and there
was no loss to follow up” (p 280)
Selective reporting (reporting bias) Unclear risk Not registered as a clinical trial, no published protocol
Other bias Unclear risk No description of participant population for baseline variability;
catheter data only
Roberts 1998
Methods RCT in a single ICU in Australia
Participants 33 participants admitted to ICU
Inclusion criteria:
• CVCs inserted in ICU
Exclusion criteria: not reported
Participants could be recruited more than once. Unit of analysis was the CVC not the
participant
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Roberts 1998 (Continued)
Interventions Group I: SPU (Opsite IV3000T M ), changed and cleansed with 0.5% chlorhexidine in
70% alcohol every 5 days and as necessary
Group II: CGI dressing (BiopatchT M ) with SPU (Opsite IV3000T M ), changed and
cleansed with 0.5% chlorhexidine in 70% alcohol every 5 days and as necessary
Outcomes • Catheter tip colonisation
• Exit-site infection
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “Randomly assigned to either the exper-
imental or the control group”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data on 7/40 participants, attrition not well
described
Selective reporting (reporting bias) High risk Did not report catheter-related infection outcomes
No registration of clinical trial or publishedprotocol
Other bias Unclear risk Baseline balance of groups: no statistically or clini-
cally significant differences in age, gender, CVC du-
ration. Other clinical variables (e.g. critical illness
severity) not stated (p 17)
Ruschulte 2009
Methods RCT in Germany
Participants 601 participants with haematological and oncological conditions
Inclusion criteria:
• triple lumen, jugular or subclavian CVCs, inserted by anaesthetic consultants
• undergoing chemotherapy for treatment of haematological and oncological
conditions
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Ruschulte 2009 (Continued)
Exclusion criteria:
• expected admission for ≤ 5 days
• previous reaction to chlorhexidine
Interventions Group I: SPU changed regularly after 7 days or if they had been lifted
Group II: CGI dressing (BiopatchTM ) with SPU. Changed regularly after 7 days or if
they had been lifted
Outcomes Catheter-related BSI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel and participants were not blinded. Quotation: “The
insertion sites were inspected and palpated daily by the specialist
oncology nurses” (p 268)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “by having nurses who were not involved in the study
assess the insertion sites and microbiologists unaware of the pa-
tients’ group assignments” (p 271)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition or loss to follow-up
Selective reporting (reporting bias) Unclear risk No registration of clinical trial or published protocol
Other bias Unclear risk Baseline balance of groups: no statistically or clinically significant
differences in age, gender, neutropenia, CVC duration (table 1,
p 269)
Shivnan 1991
Methods RCT in the USA
Participants 98 participants undergoing autologous or allogenic BMT with pre-existing or newly
inserted right atrial CVCs
Inclusion criteria:
• 2-60 years old
• haematologic malignancy or immune-deficiency disease
• pre-existing or newly inserted right atrial CVC
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Shivnan 1991 (Continued)
• admitted to the BMT unit for autologous or allogenic BMT
Exclusion criteria: not described
Interventions Group I: SPU (TegadermT M 3M) changed every 4 days
Group II: sterile gauze with tape changed daily
Both groups received gauze for the first 24 hours
Outcomes • Catheter-related BSI
• Entry- and exit-site infection
• Skin/site colonisation: day 8 of study
Notes Many skin colonisation dates reported; short term (day 8) colonisation reported within
the review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “block randomisationwithin each stratum” (p 1350)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5/103 excluded post-randomisation
27.5% required modifications of the dressing
Not stated whether intention-to-treat analysis was used
Selective reporting (reporting bias) Unclear risk No clinical trial registration or published protocol
Main study aims were assessed and reported
Other bias Unclear risk Baseline balance of groups: no statistically significant differences
(p 1352)
Sponsored by productmanufacturer (3MCompanyT M , St. Paul,
MN) manufacturer of the SPU intervention
No data on topical vancomycin use and dressing modification
for each group
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Timsit 2009
Methods RCT in France
Participants 2051 participants in ICUs
Inclusion criteria:
• CVCs or arterial catheters for > 48 hours
• > 18 years
Exclusion criteria:
• PICC
• pulmonary arterial catheters
• haemodialysis catheters
• allergy to study products
Interventions Group I: SPU dressing (TegadermTM ; 3M) changed every 3 or 7 days
Group II: CGI sponge dressing (BioPatchT M ; Ethicon Inc) with SPU changed every 3
or 7 days
Outcomes • Catheter-related BSI
• Catheter-related BSI per 1000 catheter days
• Catheter tip colonisation
Notes Published manuscript includes arterial lines; additional information provided to report
CVC-only results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “The randomization schedule, stratified by ICU,
was developed using a web-based random-number generator to
select permuted blocks of 8 patients each” (p 1232)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “The study was not blinded for the investigators or
ICU staff ” (p 1232)
Not described for participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Was blinded for the microbiologists processing the skin
and catheter cultures and for the assessors” (p 1232)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Moderate attrition, well described in CONSORT diagram (
Figure 1; p 1235)
Selective reporting (reporting bias) Unclear risk Difficult to obtain separated CVC outcomes, not originally re-
ported
Clinical trial registered via clinicaltrials.gov
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Timsit 2009 (Continued)
Other bias Unclear risk Baseline variables not reported for CVC outcomes. Balanced
critical illness severity, length of ICU stay, mechanical ventila-
tion, age for overall study as per Table 1 (p 1236)
Timsit 2012
Methods RCT in France
Participants 1879 participants in ICUs
Inclusion criteria:
• CVCs or arterial catheters for > 48 hours
• > 18 years
Exclusion criteria:
• PICC
• pulmonary arterial catheters
• haemodialysis catheters
• allergy to study products
• catheters inserted before ICU admission
Interventions Group I: SPU dressing (TegadermTM ; 3M)
Group II: CGI dressing (Tegaderm CHG IV Securement DressingT M ; 3M)
Group III: highly adhesive transparent dressing (Tegaderm HP TransparentT M ; 3M)
Outcomes • Catheter-related BSI
• Catheter-related BSI per 1000 catheter days
• Catheter tip colonisation
Notes Published manuscript includes arterial lines; additional information provided to report
CVC-only results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Randomization was by a web-based random-num-
ber generator producing permuted blocks of eight, with strati-
fication on ICUs. Each block contained four allocations to the
chlorhexidine dressing, two to the highly adhesive dressing and
two to the standard dressing. The investigators were unaware of
the block size and of the permutation procedure” (p 1273)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “The study was not blinded for the investigators or
ICU staff ” (p 1273)
Not described for participants
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Timsit 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotation: “was blinded for the microbiologists processing the
skin and catheter cultures and for the adjudication committee”
(p 1273)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Moderate attrition, well described in CONSORT diagram (
Figure 1; p 1275)
Quotation: “Analyses were performed in the intent-to-treat pop-
ulation, which included all patients except those who withdrew
their consent to study participation.” (p 1274)
Selective reporting (reporting bias) Unclear risk Difficult to obtain separated CVC outcomes, not originally re-
ported
Clinical trial registered via clinicaltrials.gov
Other bias Unclear risk Baseline variables not reported for CVC outcomes - balanced
for overall study
Supported by 3M (St Paul, MN); the manufacturer of all of the
study interventional products
Wille 1993
Methods RCT in the Netherlands
Participants 101 adult participants requiring a subclavian or jugular CVC
Inclusion criteria:
• age > 16 years,
• hospitalised for major elective surgery
Exclusion criteria: not stated
Interventions Group I: SPU (OpSiteTM ; Smith and Nephew) with moisture vapour permeability of
800 g m−². Changed regularly every 3 days.
Group II: new generation SPU (OpSite IV3000T M ; Smith and Nephew) with increased
moisture vapour permeability (2000 g m−²). Dressing changed every 3 days
Outcomes Catheter-related BSI
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Quotation: “the patients were randomized to one of the two
dressing groups” (p 114)
Allocation concealment (selection bias) Unclear risk Not described
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Wille 1993 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition poorly described. No information on missing data
Quotation: “the 13 patients not included in the analysis were
evenly distributed between the two dressing groups” (p 115)
Selective reporting (reporting bias) Unclear risk No registration of clinical trial or published protocol. All
outcomes described in publication
Other bias Unclear risk No data on co morbidities or severity of illness
Sponsored by Smith & NephewTM , Harlow, UK - product
manufacturer of both intervention groups
Yamamoto 2002
Methods RCT in the USA
Participants 170 adult participants requiring a peripherally inserted central catheter (PICC)
Inclusion criteria: not stated
Exclusion criteria: not stated
Interventions Group I: securement via 2.0 prolene sutures and standard polyurethane dressing (SPU)
. Changed regularly every 3 days or more frequently if necessary
Group II: securement via a SSD (StatLockT M ) and SPU. Dressing changed every 3 days,
SSD every 6 days
When participant discharged home, dressings changed weekly
Outcomes • Catheter-related BSI
• Skin irritation or damage: cellulitis; tenderness, erythema, oedema, purulent
exudate (p 78)
• Failed catheter securement: accidental removal or movement that resulted in the
loss of function (p 78)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not stated in publication
Private correspondence: “using blinded envelopes”
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Yamamoto 2002 (Continued)
Allocation concealment (selection bias) Low risk Quotation: “concealed envelopes distributed to research assis-
tants” (p 78)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors for dislodgement and skin damage not
blinded
Not stated whether microbiology outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up and attrition not stated
Selective reporting (reporting bias) Unclear risk No registration of clinical trial or published protocol
Other bias Unclear risk Research sponsored by StatLock product manufacturer (Venetec
International, San Diego, CA)
Abbreviations
BMT: bone marrow transplant
CGI: chlorhexidine-impregnated
CVC: central venous catheter
ICU: intensive care unit
PICC: peripherally-inserted central catheter
RCT: randomised controlled trial
SPU: standard polyurethane
SSD: sutureless securement device
TPN: total parenteral nutrition
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Crawford 2004 No outcomes that accorded with our review definitions: cost-related data only
Davidson 1986 Nooutcomes reported that accordedwith our review definitions: no definitions of blood and skin cultures provided
Freiberger 1992 Results not reported by intervention group
Skin/site swab with any bacterial growth included: not positive semi-quantitative (> 15 cfu) or quantitative (> 10³
cfu) culture from the skin around the catheter site (O’Grady 2002)
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(Continued)
George 2011 No outcomes reported that accorded with our review definitions: no definition or assessment tool to evaluate skin
irritation or damage
Keenlyside 1991 No outcomes reported that accorded with our review definitions: no definition or assessment tool to evaluate
dressing condition, skin irritation or damage
Keenlyside 1993 Duplicate publication from Keenlyside 1991: no outcomes that accorded with our review definitions
Khattak 2010 No outcomes that accorded with our review definitions: all blood cultures included, not catheter-related BSI
Lawson 1986 No outcomes that accorded with our review definitions: no definition or assessment tool to evaluate skin irritation,
damage or infection
Little 1998 Inadequate data for extraction
Lucas 1996 No outcomes that accorded with our review definitions: no definition regarding microbiological criteria for skin/
site colonisation
Madeo 1998 Arterial and CVC outcomes reported together; unable to extract CVC outcomes
Maki 1984 Not a RCT
Maki 2000 Arterial and CVC outcomes reported together; unable to extract CVC outcomes
Neufeld 1991 No outcomes that accorded with our review definitions: no definition regarding microbiological criteria for skin/
site colonisation
Olson 2008 No outcomes as per our review definitions: outcome assessments used to describe skin irritation or damage did
not have established reliability
Petrosino 1988 No outcomes that accorded with our review definitions: described skin/site colonisation without microbiological
definition
Powell 1982 No outcomes that accorded with our review definitions. Catheter-related BSI not in accordance with review
outcome definitions
Powell 1985 Extreme confounders involving the use of specific dosages of skin antisepsis and administration set change intervals
within the interventions
Reynolds 1997 CCT not RCT (sequential assignment)
Schwebel 2012 No outcomes as per our review definitions: cost-related data only
Timsit 2010 No outcomes as per our review definitions: cost-related data only
65Dressings and securement devices for central venous catheters (CVC) (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of studies awaiting assessment [ordered by study ID]
Broadhurst 2014
Methods
Participants
Interventions
Outcomes
Notes authors contacted for further information
Calvino 2014
Methods
Participants
Interventions
Outcomes
Notes authors contacted for further information
Gu 2014
Methods
Participants
Interventions
Outcomes
Notes authors contacted for further information
Pedrolo 2014
Methods
Participants
Interventions
Outcomes
Notes authors contacted for further information
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D A T A A N D A N A L Y S E S
Comparison 1. Primary analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter-related blood stream
infection
14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Gauze and tape versus
SPU
8 506 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.26, 1.63]
1.2 CGI versus SPU 5 4876 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.40, 1.05]
1.3 Medication-impregnated
dressings versus all others
6 5687 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.39, 0.93]
2 Frequency of catheter-related
BSI per 1000 patient days
6 Rate Ratio (Random, 95% CI) Subtotals only
2.1 Gauze and tape versus
SPU
2 Rate Ratio (Random, 95% CI) 0.71 [0.20, 2.52]
2.2 CGI versus SPU 4 Rate Ratio (Random, 95% CI) 0.51 [0.33, 0.78]
3 Catheter tip colonisation 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Gauze and tape versus
SPU
5 342 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.51, 1.77]
3.2 CGI versus SPU 6 4431 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.47, 0.73]
4 Entry- and exit-site infection 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Gauze and tape versus
SPU
2 199 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.34, 2.07]
5 Skin/site colonisation 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Gauze and tape versus
SPU
2 170 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.30, 2.51]
6 Skin irritation or damage 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 CGI versus SPU 2 850 Risk Ratio (M-H, Random, 95% CI) 11.17 [0.84, 149.48]
7 Failed catheter securement 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Gauze and tape versus
SPU
2 167 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.33, 2.49]
Comparison 2. Sensitivity analysis: studies at low risk of bias
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter tip colonisation 4 4253 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.46, 0.77]
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Analysis 1.1. Comparison 1 Primary analysis, Outcome 1 Catheter-related blood stream infection.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 1 Primary analysis
Outcome: 1 Catheter-related blood stream infection
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gauze and tape versus SPU
Brandt 1996 1/53 5/48 16.5 % 0.18 [ 0.02, 1.50 ]
Conly 1989 0/34 7/42 9.8 % 0.08 [ 0.00, 1.38 ]
de Barros 2009 3/33 4/33 31.3 % 0.75 [ 0.18, 3.09 ]
Giles 2002 0/39 0/33 Not estimable
Hagerstrom 1994 2/7 0/7 9.5 % 5.00 [ 0.28, 88.53 ]
le Corre 2003 2/29 1/29 13.8 % 2.00 [ 0.19, 20.86 ]
Pedrolo 2011 1/10 1/11 11.2 % 1.10 [ 0.08, 15.36 ]
Shivnan 1991 0/47 1/51 7.9 % 0.36 [ 0.02, 8.65 ]
Subtotal (95% CI) 252 254 100.0 % 0.64 [ 0.26, 1.63 ]
Total events: 9 (Experimental), 19 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 6.82, df = 6 (P = 0.34); I2 =12%
Test for overall effect: Z = 0.93 (P = 0.35)
2 CGI versus SPU
Arvaniti 2012 3/150 2/156 6.8 % 1.56 [ 0.26, 9.21 ]
Garland 2001 12/314 11/341 24.7 % 1.18 [ 0.53, 2.65 ]
Ruschulte 2009 19/300 34/301 39.6 % 0.56 [ 0.33, 0.96 ]
Timsit 2009 5/1056 10/995 16.2 % 0.47 [ 0.16, 1.37 ]
Timsit 2012 5/980 5/283 12.8 % 0.29 [ 0.08, 0.99 ]
Subtotal (95% CI) 2800 2076 100.0 % 0.65 [ 0.40, 1.05 ]
Total events: 44 (Experimental), 62 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 5.38, df = 4 (P = 0.25); I2 =26%
Test for overall effect: Z = 1.78 (P = 0.076)
3 Medication-impregnated dressings versus all others
Arvaniti 2012 3/150 2/156 5.6 % 1.56 [ 0.26, 9.21 ]
Chambers 2005 2/58 7/54 7.4 % 0.27 [ 0.06, 1.22 ]
Garland 2001 12/314 11/341 21.7 % 1.18 [ 0.53, 2.65 ]
Ruschulte 2009 19/300 34/301 36.7 % 0.56 [ 0.33, 0.96 ]
0.01 0.1 1 10 100
Favours experimental Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Timsit 2009 5/1056 10/995 13.8 % 0.47 [ 0.16, 1.37 ]
Timsit 2012 5/980 14/982 15.0 % 0.36 [ 0.13, 0.99 ]
Subtotal (95% CI) 2858 2829 100.0 % 0.60 [ 0.39, 0.93 ]
Total events: 46 (Experimental), 78 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 6.21, df = 5 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.28 (P = 0.022)
Test for subgroup differences: Chi2 = 0.05, df = 2 (P = 0.98), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.2. Comparison 1 Primary analysis, Outcome 2 Frequency of catheter-related BSI per 1000
patient days.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 1 Primary analysis
Outcome: 2 Frequency of catheter-related BSI per 1000 patient days
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Gauze and tape versus SPU
de Barros 2009 -0.6472 (0.7608) 72.1 % 0.52 [ 0.12, 2.33 ]
le Corre 2003 0.4462 (1.2245) 27.9 % 1.56 [ 0.14, 17.22 ]
Subtotal (95% CI) 100.0 % 0.71 [ 0.20, 2.52 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
2 CGI versus SPU
Arvaniti 2012 0.4944 (0.9119) 6.0 % 1.64 [ 0.27, 9.79 ]
Ruschulte 2009 -0.6315 (0.2857) 61.2 % 0.53 [ 0.30, 0.93 ]
Timsit 2009 -0.8308 (0.5475) 16.7 % 0.44 [ 0.15, 1.27 ]
Timsit 2012 -1.1654 (0.5575) 16.1 % 0.31 [ 0.10, 0.93 ]
0.01 0.1 1 10 100
Favours experimental Favours SPU
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(. . . Continued)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 100.0 % 0.51 [ 0.33, 0.78 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours SPU
Analysis 1.3. Comparison 1 Primary analysis, Outcome 3 Catheter tip colonisation.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 1 Primary analysis
Outcome: 3 Catheter tip colonisation
Study or subgroup Experimental SPU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gauze and tape versus SPU
Carrer 2005 32/54 35/53 31.7 % 0.90 [ 0.67, 1.20 ]
Conly 1989 8/34 26/42 24.8 % 0.38 [ 0.20, 0.73 ]
de Barros 2009 3/33 4/33 12.3 % 0.75 [ 0.18, 3.09 ]
Giles 2002 7/39 3/33 14.0 % 1.97 [ 0.55, 7.03 ]
Pedrolo 2011 7/10 3/11 17.3 % 2.57 [ 0.90, 7.31 ]
Subtotal (95% CI) 170 172 100.0 % 0.95 [ 0.51, 1.77 ]
Total events: 57 (Experimental), 71 (SPU)
Heterogeneity: Tau2 = 0.29; Chi2 = 12.06, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 0.16 (P = 0.87)
2 CGI versus SPU
Arvaniti 2012 21/150 24/156 13.5 % 0.91 [ 0.53, 1.56 ]
Garland 2001 47/314 82/341 28.7 % 0.62 [ 0.45, 0.86 ]
Levy 2005 11/74 21/71 9.8 % 0.50 [ 0.26, 0.97 ]
0.01 0.1 1 10 100
Favours experimental Favours SPU
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(. . . Continued)
Study or subgroup Experimental SPU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Roberts 1998 2/17 1/16 0.9 % 1.88 [ 0.19, 18.80 ]
Timsit 2009 60/1056 123/995 32.0 % 0.46 [ 0.34, 0.62 ]
Timsit 2012 45/980 20/261 15.0 % 0.60 [ 0.36, 1.00 ]
Subtotal (95% CI) 2591 1840 100.0 % 0.58 [ 0.47, 0.73 ]
Total events: 186 (Experimental), 271 (SPU)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.41, df = 5 (P = 0.27); I2 =22%
Test for overall effect: Z = 4.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.09, df = 1 (P = 0.15), I2 =52%
0.01 0.1 1 10 100
Favours experimental Favours SPU
Analysis 1.4. Comparison 1 Primary analysis, Outcome 4 Entry- and exit-site infection.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 1 Primary analysis
Outcome: 4 Entry- and exit-site infection
Study or subgroup Gauze % tape SPU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gauze and tape versus SPU
Brandt 1996 7/53 7/48 85.6 % 0.91 [ 0.34, 2.39 ]
Shivnan 1991 1/47 2/51 14.4 % 0.54 [ 0.05, 5.79 ]
Subtotal (95% CI) 100 99 100.0 % 0.84 [ 0.34, 2.07 ]
Total events: 8 (Gauze % tape), 9 (SPU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.5. Comparison 1 Primary analysis, Outcome 5 Skin/site colonisation.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 1 Primary analysis
Outcome: 5 Skin/site colonisation
Study or subgroup Gauze % tape SPU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gauze and tape versus SPU
Giles 2002 2/39 1/33 20.6 % 1.69 [ 0.16, 17.84 ]
Shivnan 1991 4/47 6/51 79.4 % 0.72 [ 0.22, 2.41 ]
Subtotal (95% CI) 86 84 100.0 % 0.86 [ 0.30, 2.51 ]
Total events: 6 (Gauze % tape), 7 (SPU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.6. Comparison 1 Primary analysis, Outcome 6 Skin irritation or damage.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 1 Primary analysis
Outcome: 6 Skin irritation or damage
Study or subgroup CGI SPU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CGI versus SPU
Garland 2001 19/335 0/370 44.2 % 43.06 [ 2.61, 710.44 ]
Levy 2005 4/74 1/71 55.8 % 3.84 [ 0.44, 33.51 ]
Subtotal (95% CI) 409 441 100.0 % 11.17 [ 0.84, 149.48 ]
Total events: 23 (CGI), 1 (SPU)
Heterogeneity: Tau2 = 1.92; Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CGI Favours SPU
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Analysis 1.7. Comparison 1 Primary analysis, Outcome 7 Failed catheter securement.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 1 Primary analysis
Outcome: 7 Failed catheter securement
Study or subgroup Gauze % tape SPU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gauze and tape versus SPU
Brandt 1996 5/53 6/48 81.5 % 0.75 [ 0.25, 2.31 ]
de Barros 2009 2/33 1/33 18.5 % 2.00 [ 0.19, 21.00 ]
Subtotal (95% CI) 86 81 100.0 % 0.90 [ 0.33, 2.49 ]
Total events: 7 (Gauze % tape), 7 (SPU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours gauze % tape Favours SPU
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Analysis 2.1. Comparison 2 Sensitivity analysis: studies at low risk of bias, Outcome 1 Catheter tip
colonisation.
Review: Dressings and securement devices for central venous catheters (CVC)
Comparison: 2 Sensitivity analysis: studies at low risk of bias
Outcome: 1 Catheter tip colonisation
Study or subgroup CGI SPU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arvaniti 2012 21/150 24/156 16.8 % 0.91 [ 0.53, 1.56 ]
Garland 2001 47/314 82/341 31.1 % 0.62 [ 0.45, 0.86 ]
Timsit 2009 60/1056 123/995 33.8 % 0.46 [ 0.34, 0.62 ]
Timsit 2012 45/980 20/261 18.3 % 0.60 [ 0.36, 1.00 ]
Total (95% CI) 2500 1753 100.0 % 0.59 [ 0.46, 0.77 ]
Total events: 173 (CGI), 249 (SPU)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.23, df = 3 (P = 0.16); I2 =43%
Test for overall effect: Z = 3.89 (P = 0.000099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CGI Favours SPU
A P P E N D I C E S
Appendix 1. Types of central venous catheters (CVCs) used
Catheter type Entry site Length
Non-tunnelled central venous catheters Percutaneously inserted into central veins
(subclavian, internal jugular or femoral)
≥ 8 cm depending on patient size
Peripherally inserted central venous
catheters (PICC)
Inserted into basilic, cephalic or brachial
veins and enter the superior vena cava
≥ 20 cm depending on patient size
Tunnelled central venous catheters Implanted into subclavian, internal jugular,
or femoral veins
≥ 8 cm depending on patient size
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(Continued)
Totally implantable Tunnelled beneath skin and have subcu-
taneous port accessed with a needle; im-
planted in subclavian or internal jugular
vein
≥ 8 cm depending on patient size
O’Grady 2011 pg. 22
≥ = greater than or equal to
Appendix 2. Additional search strategy
Ovid MEDLINE
1 exp Catheterization, Central Venous/ (12023)
2 (venous adj3 (catheter* or line*)).tw. (12967)
3 (central adj3 (catheter* or line*)).tw. (12809)
4 ((hickman or broviac or cook) adj catheter*).tw. (667)
5 exp Catheters, Indwelling/ (16113)
6 (implantable vascular access device or IAVD or PortACath).tw. (58)
7 (peripherally inserted central catheter or PICC).tw. (585)
8 h?emodialysis catheter*.tw. (762)
9 or/1-8 (34316)
10 exp Occlusive Dressings/ (3511)
11 exp Bandages, Hydrocolloid/ (631)
12 exp Silver/ (14667)
13 exp Silver Sulfadiazine/ (809)
14 exp Polyurethanes/ (7439)
15 exp Iodine/ (18302)
16 exp Chlorhexidine/ (6308)
17 ((occlusive* or hydrocolloid* or silver* or polyurethane* or permeable or nonpermeable or non-permeable or transparent or
chlorhexidine or iodine* or gauze or tape) adj3 (dressing* or sponge*)).tw. (2517)
18 or/10-17 (51952)
19 9 and 18 (748)
20 randomized controlled trial.pt. (387973)
21 controlled clinical trial.pt. (89778)
22 randomi?ed.ab. (340534)
23 placebo.ab. (150625)
24 clinical trials as topic.sh. (173007)
25 randomly.ab. (200735)
26 trial.ti. (123439)
27 or/20-26 (904765)
28 exp animals/ not humans.sh. (4009223)
29 27 not 28 (832096)
30 19 and 29 (224)
31 2014*.ed. (584053)
32 30 and 31 (3)
Ovid EMBASE
1 exp central venous catheter/ (12794)
2 exp central venous catheterization/ (7021)
3 (venous adj3 (catheter* or line*)).tw. (18144)
4 (central adj3 (catheter* or line*)).tw. (19024)
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5 ((hickman or broviac or cook) adj catheter*).tw. (776)
6 exp vascular access device/ (12794)
7 (implantable vascular access device or IAVD or PortACath).tw. (102)
8 (peripherally inserted central catheter or PICC).tw. (1340)
9 h?emodialysis catheter*.tw. (1069)
10 or/1-9 (31589)
11 exp occlusive dressing/ (508)
12 exp hydrocolloid dressing/ (628)
13 exp silver/ (27276)
14 exp sulfadiazine silver/ (3015)
15 exp sulfathiazole silver/ (19)
16 exp polyurethan/ (9963)
17 exp iodine/ (36182)
18 exp chlorhexidine/ (12160)
19 ((occlusive* or hydrocolloid* or silver* or polyurethane* or permeable or nonpermeable or non-permeable or transparent or
chlorhexidine or iodine* or gauze or tape) adj3 (dressing* or sponge*)).tw. (3408)
20 or/11-19 (89926)
21 10 and 20 (1216)
22 Randomized controlled trials/ (57946)
23 Single-Blind Method/ (18790)
24 Double-Blind Method/ (117793)
25 Crossover Procedure/ (40165)
26 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab. (1366645)
27 (doubl$ adj blind$).ti,ab. (149833)
28 (singl$ adj blind$).ti,ab. (14881)
29 or/22-28 (1437406)
30 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/ (20630118)
31 human/ or human cell/ (15052414)
32 and/30-31 (15005735)
33 30 not 32 (5624383)
34 29 not 33 (1242391)
35 21 and 34 (220)
36 2014*.em. (1159417)
37 35 and 36 (14)
EBSCO CINAHL
S38S25 AND S37
S37S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36
S36TX allocat* random*
S35(MH “Quantitative Studies”)
S34(MH “Placebos”)
S33TX placebo*
S32TX random* allocat*
S31(MH “Random Assignment”)
S30TX randomi* control* trial*
S29TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S28TX clinic* n1 trial*
S27PT Clinical trial
S26(MH “Clinical Trials+”)
S25S11 and S24
S24S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23
S23TI ( occlusive* N3 sponge* or hydrocolloid* N3 sponge* or silver* N3 sponge* or polyurethane* N3 sponge* or permeable N3
sponge* or nonpermeable N3 sponge* or non-permeable N3 sponge* or transparent N3 sponge* or chlorhexidine N3 sponge* or
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iodine* N3 sponge* or gauze N3 sponge* or tape N3 sponge* N3 sponge* ) OR AB ( occlusive* N3 sponge* or hydrocolloid* N3
sponge* or silver* N3 sponge* or polyurethane* N3 sponge* or permeable N3 sponge* or nonpermeable N3 sponge* or non-permeable
N3 sponge* or transparent N3 sponge* or chlorhexidine N3 sponge* or iodine* N3 sponge* or gauze N3 sponge* or tape N3 sponge*
N3 sponge* )
S22TI ( occlusive* N3 dressing* or hydrocolloid* N3 dressing* or silver* N3 dressing* or polyurethane* N3 dressing* or permeable N3
dressing* or nonpermeable N3 dressing* or non-permeable N3 dressing* or transparent N3 dressing* or chlorhexidine N3 dressing*
or iodine* N3 dressing* or gauze N3 dressing* or tape N3 dressing*) OR AB (occlusive* N3 dressing* or hydrocolloid* N3 dressing*
or silver* N3 dressing* or polyurethane* N3 dressing* or permeable N3 dressing* or nonpermeable N3 dressing* or non-permeable
N3 dressing* or transparent N3 dressing* or chlorhexidine N3 dressing* or iodine* N3 dressing* or gauze N3 dressing* or tape N3
dressing*)
S21(MH “Chlorhexidine”)
S20(MH “Iodine”)
S19(MH “Transparent Dressings”)
S18(MH “Polyurethanes”)
S17(MH “Gauze Dressings”)
S16(MH “Ionic Silver Dressings”)
S15(MH “Silver Sulfadiazine”)
S14(MH “Silver”)
S13(MH “Hydrocolloid Dressings”)
S12(MH “Occlusive Dressings”)
S11S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10
S10TI ( hemodialysis catheter* or haemodialysis catheter* ) OR AB ( hemodialysis catheter* or haemodialysis catheter* )
S9TI ( peripherally inserted central catheter or PICC ) OR AB ( peripherally inserted central catheter or PICC )
S8TI ( implantable vascular access device or IAVD or PortACath ) OR AB ( implantable vascular access device or IAVD or PortACath
)
S7(MH “Vascular Access Devices, Implantable”)
S6TI cook catheter* OR AB cook catheter*
S5TI broviac catheter* OR AB broviac catheter*
S4TI hickman catheter* OR AB hickman catheter*
S3TI ( central N3 (catheter* or line*) ) OR AB ( central N3 (catheter* or line*) )
S2TI ( venous N3 (catheter* or line*) ) OR AB ( venous N3 (catheter* or line*) )
S1(MH “Central Venous Catheters+”)
F E E D B A C K
Feedback from Tom Macmillan, Information Specialist, 11 August 2016
Summary
Comment: I believe there is an error in your analysis in section 1.1.8. The text states:
“There were fewer cases of catheter-related BSI with SPU than sutureless securement devices in a single study in adult general acute
and home care settings.”
This references Yamamto et al. (2002); however, looking at the original paper the result is the complete opposite. They found fewer
suspected and confirmed cases of CRBSI with the sutureless securement device (both statistically significant results).
Although this is not the main focus of the study, I think it probably merits a correction.
Reply
Many thanks to Tom MacMillan for alerting us to an error when summarising the results of a single study (Yamamoto 2002) included
within our review examining central venous catheter dressing and securement. The data from this study were correctly included within
each of the network meta-analyses, however the individual results within the outcome of catheter-related BSI were inverted. We have
now corrected this mistake within the appropriate results section of the text. We wish to apologise for any confusion caused.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Our protocol planned to calculate hazard ratios (HR) to estimate the effect of interventions for time-to-event data. HR can only be
calculated from full data sets, log-rank results, KaplanMeier curves or Cox results. Instead we have calculated Incidence Rate Ratio,
which is also appropriate for time-to-event data as it considers the at-risk periods (Deeks 2011; Parmar 1998).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Bandages; ∗Central Venous Catheters; Catheter-Related Infections [∗prevention & control]; Catheterization, Central Venous [instru-
mentation; ∗methods]; Chlorhexidine [administration & dosage; analogs & derivatives]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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